PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION

**DuPizent®**

dupilumab injection

solution for subcutaneous injection

300 mg single-use syringe (300 mg/2 mL)
300 mg single-use pen (300 mg/2 mL)
200 mg single-use syringe (200 mg/1.14 mL)

Immunomodulator, Interleukin inhibitor

Sanofi-aventis Canada Inc.
2905 Place Louis-R-Renaud
Laval, Quebec H7V0A3

Distributed by Sanofi Genzyme,
a division of sanofi-aventis Canada Inc.
800-2700 Matheson Blvd East
Mississauga, ON L4W 4V9

Date of Initial Approval: November 30, 2017

Submission Control No: 239184

Date of Revision: December 23, 2020
Table of Contents

PART I: HEALTH PROFESSIONAL INFORMATION

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>SUMMARY PRODUCT INFORMATION</td>
<td>3</td>
</tr>
<tr>
<td>DESCRIPTION</td>
<td>3</td>
</tr>
<tr>
<td>INDICATIONS AND CLINICAL USE</td>
<td>3</td>
</tr>
<tr>
<td>CONTRAINDICATIONS</td>
<td>5</td>
</tr>
<tr>
<td>WARNINGS AND PRECAUTIONS</td>
<td>5</td>
</tr>
<tr>
<td>ADVERSE REACTIONS</td>
<td>8</td>
</tr>
<tr>
<td>DRUG INTERACTIONS</td>
<td>13</td>
</tr>
<tr>
<td>DOSAGE AND ADMINISTRATION</td>
<td>14</td>
</tr>
<tr>
<td>OVERDOSAGE</td>
<td>16</td>
</tr>
<tr>
<td>ACTION AND CLINICAL PHARMACOLOGY</td>
<td>16</td>
</tr>
<tr>
<td>STORAGE AND STABILITY</td>
<td>20</td>
</tr>
<tr>
<td>SPECIAL HANDLING INSTRUCTIONS</td>
<td>20</td>
</tr>
<tr>
<td>DOSAGE FORMS, COMPOSITION AND PACKAGING</td>
<td>22</td>
</tr>
</tbody>
</table>

PART II: SCIENTIFIC INFORMATION

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>PHARMACEUTICAL INFORMATION</td>
<td>23</td>
</tr>
<tr>
<td>CLINICAL TRIALS</td>
<td>24</td>
</tr>
<tr>
<td>DETAILED PHARMACOLOGY</td>
<td>45</td>
</tr>
<tr>
<td>TOXICOLOGY</td>
<td>45</td>
</tr>
<tr>
<td>REFERENCES</td>
<td>46</td>
</tr>
</tbody>
</table>

PART III: PATIENT MEDICATION INFORMATION

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>INSTRUCTIONS FOR USE</td>
<td>55</td>
</tr>
<tr>
<td>DUPIXENT 300 mg SINGLE-DOSE PRE-FILLED SYRINGE WITH NEEDLE SHIELD</td>
<td>55</td>
</tr>
</tbody>
</table>

INSTRUCTIONS FOR USE

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>DUPIXENT 200 mg SINGLE-DOSE PRE-FILLED SYRINGE WITH NEEDLE SHIELD</td>
<td>65</td>
</tr>
<tr>
<td>DUPIXENT 300 mg SINGLE-DOSE PRE-FILLED SYRINGE</td>
<td>74</td>
</tr>
</tbody>
</table>

INSTRUCTIONS FOR USE

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>DUPIXENT 300 mg SINGLE-DOSE PRE-FILLED PEN</td>
<td>83</td>
</tr>
</tbody>
</table>
**DUPIXENT®**

dupilumab injection

solution for subcutaneous injection

300 mg single-use syringe (300 mg/2 mL)
300 mg single-use pen (300 mg/2 mL)
200 mg single-use syringe (200 mg/1.14 mL)

**PART I: HEALTH PROFESSIONAL INFORMATION**

**SUMMARY PRODUCT INFORMATION**

<table>
<thead>
<tr>
<th>Route of Administration</th>
<th>Dosage Form / Strength</th>
<th>Clinically Relevant Nonmedicinal Ingredients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subcutaneous injection</td>
<td>Solution:</td>
<td>L-arginine hydrochloride, L-histidine, polysorbate 80, sodium acetate, sucrose, acetic acid for pH adjustment, water for injection. For a complete listing see Dosage Forms, Composition and Packaging section.</td>
</tr>
<tr>
<td></td>
<td>- 150 mg/mL (300 mg/2 mL): pre-filled syringe with needle shield (PFS-S), pre-filled syringe (PFS) or pre-filled pen (PFP)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- 175 mg/mL (200 mg/1.14 mL): pre-filled syringe with needle shield (PFS-S)</td>
<td></td>
</tr>
</tbody>
</table>

**DESCRIPTION**

DUPIXENT (dupilumab injection) is a recombinant human IgG4 monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by specifically binding to the IL-4Rα subunit shared by the IL-4 and IL-13 receptor complexes. DUPIXENT inhibits IL-4 signaling via the Type I receptor (IL-4Rα/γc), and both IL-4 and IL-13 signaling through the Type II receptor (IL-4Rα/IL-13Rα).

**INDICATIONS AND CLINICAL USE**

**Atopic Dermatitis**

DUPIXENT is indicated for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

DUPIXENT can be used with or without topical corticosteroids.
**Asthma**

DUPIXENT is indicated as an add-on maintenance treatment in patients aged 12 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma.

**DUPIXENT is not indicated for relief of acute bronchospasm or status asthmaticus (see WARNINGS AND PRECAUTIONS)**

**Chronic Rhinosinusitis with Nasal Polyposis**

DUPIXENT is indicated as an add-on maintenance treatment with intranasal corticosteroids in adult patients with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) inadequately controlled by systemic corticosteroids and/or surgery.

**Geriatrics (≥65 years of age):**

**Atopic Dermatitis**

Of the 1472 patients with atopic dermatitis exposed to DUPIXENT in a phase 2 dose-ranging study or phase 3 placebo-controlled studies, a total of 67 were 65 years or older. Although no differences in efficacy or safety were observed between older and younger patients, the number of patients aged 65 and over is not sufficient to determine whether they respond differently from younger patients (see ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions). No dose adjustment is recommended for elderly patients.

**Asthma**

Of the 1977 patients with asthma exposed to DUPIXENT, a total of 240 patients were 65 years or older and 39 patients were 75 years or older. Efficacy and safety in this age group was consistent with the overall study population.

**Chronic Rhinosinusitis with Nasal Polyposis**

Of the 440 patients with CRSwNP exposed to DUPIXENT, at total of 79 were 65 years and older. Efficacy and safety in this age group were consistent with the overall study population. A total of 11 patients were 75 years and older (see ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions). No dose adjustment is recommended for elderly patients.

**Pediatrics (<18 years of age):**

**Atopic Dermatitis**

Efficacy and safety of DUPIXENT in pediatric patients with atopic dermatitis below the age of 12 years have not been established.

**Asthma**

Efficacy and safety in pediatric patients with asthma below the age of 12 years have not been established.
**Chronic Rhinosinusitis with Nasal Polyposis**
Efficacy and safety of DUPIXENT in pediatric patients with CRSwNP have not been established.

**CONTRAINDICATIONS**
DUPIXENT is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see the DOSAGE FORMS, COMPOSITION AND PACKAGING section of the product monograph.

**WARNINGS AND PRECAUTIONS**

**General**

*Acute Asthma Symptoms or Deteriorating Disease*
DUPIXENT (dupilumab injection) should not be used to treat acute asthma symptoms or acute exacerbations. Do not use DUPIXENT to treat acute bronchospasm or status asthmaticus.

Patients should be instructed to seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with DUPIXENT.

*Reduction of Corticosteroid Dosage*
Do not discontinue systemic, topical, or inhaled corticosteroids abruptly upon initiation of treatment with DUPIXENT. Reductions in corticosteroid dose, if appropriate, should be gradual and only performed under the supervision of a healthcare professional. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or may unmask conditions previously suppressed by systemic corticosteroid therapy.

Patients with atopic dermatitis or CRSwNP who have comorbid asthma should be advised not to adjust or stop their asthma treatments without consulting their healthcare professional.

**Immune**

*Hypersensitivity*
Hypersensitivity reactions, including anaphylaxis, serum sickness or serum sickness-like reactions and angioedema, some of which have been serious, have been reported following the use of DUPIXENT. If a systemic hypersensitivity reaction occurs, including generalized urticaria, and rash, erythema nodosum, serum sickness or serum-sickness-like reactions (occurred in less than 1% of subjects who received DUPIXENT in clinical trials), administration of DUPIXENT should be discontinued immediately and appropriate therapy initiated. One case of anaphylaxis has been reported in the asthma development program following the administration of DUPIXENT (see ADVERSE REACTIONS).
**Eosinophilic Conditions**
DUPIXENT has been associated with an elevation of blood eosinophils. Patients being treated for asthma may present with serious systemic eosinophilia sometimes presenting with clinical features of eosinophilic pneumonia or vasculitis consistent with eosinophilic granulomatosis with polyangiitis, conditions that are often treated with systemic corticosteroids. These events usually, but not always, may be associated with the reduction of oral corticosteroid therapy.

Cases of eosinophilic pneumonia were reported with DUPIXENT in adult subjects who participated in the asthma development program and cases of vasculitis consistent with eosinophilic granulomatosis with polyangiitis have been reported in subjects who participated in the asthma development program as well as in adult subjects with co-morbid asthma receiving DUPIXENT in the CRSwNP development program. Healthcare professionals should be alert to vasculitic rash, worsening pulmonary symptoms, cardiac complications, and/or neuropathy presenting in patients with eosinophilia. A causal association between DUPIXENT and these conditions has not been established.

**Helminth Infection**
Patients with known helminth infections were excluded from participation in clinical studies. It is unknown if DUPIXENT will influence the immune response against helminth infections. Treat patients with pre-existing helminth infections before initiating DUPIXENT. If patients become infected while receiving treatment with DUPIXENT and do not respond to anti-helminth treatment, discontinue treatment with DUPIXENT until infection resolves.

**Conjunctivitis and Keratitis**
Conjunctivitis and keratitis occurred more frequently in subjects who received DUPIXENT. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis recovered or were recovering during the treatment period (see ADVERSE REACTIONS). Keratitis was reported in <1% of the DUPIXENT group (1 per 100 subject-years) in the 16-week monotherapy trials. In the 52-week DUPIXENT + topical corticosteroids (TCS) trial, keratitis was reported in 4% of the DUPIXENT + TCS group (12 per 100 subject-years). Most subjects with keratitis recovered or were recovering during the treatment period. Among asthma subjects, the frequency of conjunctivitis was low and consistent between DUPIXENT and placebo. In subjects with CRSwNP, the frequency of conjunctivitis was 2% in the DUPIXENT group compared to 1% in the placebo group in the 24-week safety pool; these subjects recovered. There were no cases of keratitis reported in the CRSwNP development program.

Advise patients to report new onset or worsening eye symptoms to their healthcare professional.

**Concomitant Atopic Conditions**
Patients with atopic dermatitis and comorbid asthma should be advised not to adjust their treatment without consultation with their healthcare professional. If discontinuing DUPIXENT, consider the potential effects on other atopic conditions.
Special Populations

**Pregnant Women:**
No studies have been conducted with DUPIXENT in pregnant women and relevant data from clinical use are very limited. Human IgG antibodies are known to cross the placental barrier; therefore, DUPIXENT may be transmitted from the mother to the developing fetus. An enhanced pre- and post-natal study exposing pregnant cynomolgus monkeys to a surrogate antibody against IL-4Rα during organogenesis through parturition did not reveal any developmental effects in offspring (see Toxicology).

**Nursing Women:**
There is no information regarding the presence of DUPIXENT in human breast milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for DUPIXENT and any potential adverse effects on the breastfed child from DUPIXENT or from the underlying maternal condition.

**Pediatrics (≥ 12 years of age):**

**Atopic Dermatitis**
Efficacy and safety of DUPIXENT in pediatric patients with atopic dermatitis below the age of 12 years have not been established.

**Asthma**
Efficacy and safety in pediatric patients with asthma below the age of 12 years have not been established.

For 107 adolescents aged 12 to 17 years with asthma (68 exposed to dupilumab), the safety profile was consistent with the overall adult population.

**Chronic Rhinosinusitis with Nasal Polyposis**
Efficacy and safety in pediatric subjects (<18 years of age) with CRSwNP have not been established.

**Geriatrics (> 65 years of age):**

**Atopic Dermatitis**
Of the 1472 patients with atopic dermatitis exposed to DUPIXENT in a phase 2 dose-ranging study or phase 3 placebo-controlled studies, a total of 67 were 65 years or older. Although no differences in efficacy or safety were observed between older and younger subjects, the number of subjects aged 65 and over is not sufficient to determine whether they respond differently from younger subjects.

**Asthma**
Of the 1977 patients with asthma exposed to DUPIXENT, a total of 240 patients were 65 years or older and 39 patients were 75 years or older. Efficacy and safety in this age group was consistent with the overall study population.
Chronic Rhinosinusitis with Nasal Polyposis
Of the 440 subjects with CRSwNP exposed to DUPIXENT, at total of 79 were 65 years and older. Efficacy and safety in this age group were consistent with the overall study population. A total of 11 subjects were 75 years and older. No dose adjustment is recommended for elderly patients.

ADVERSE REACTIONS

Clinical Trial Adverse Drug Reactions

Because clinical trials are conducted under very specific conditions the adverse reaction rates observed in the clinical trials may not reflect the rates observed in practice and should not be compared to the rates in the clinical trials of another drug. Adverse drug reaction information from clinical trials is useful for identifying drug-related adverse events and for approximating rates.

Atopic Dermatitis

Adults
In the overall exposure pool, a total of 2526 subjects with atopic dermatitis were treated with DUPIXENT in controlled and uncontrolled clinical trials. Of these, 739 subjects were exposed for at least 1 year.

The safety of DUPIXENT monotherapy was evaluated through week 16 based on data from three randomized, double-blind, placebo-controlled multicenter studies (SOLO 1, SOLO 2, and a phase 2, dose-ranging study) that included 1564 adult subjects with moderate-to-severe atopic dermatitis (AD). The study population had a mean age of 38.2 years, 41.1 % was female, 67.9 % white, 21.9 % Asian, 7.1% black, and reported co-morbid atopic conditions such as asthma (39.6%), allergic rhinitis (49.0%), food allergy (37.3%), and allergic conjunctivitis (23.1%).

The safety of DUPIXENT with concomitant topical corticosteroids (TCS) was evaluated based on data from one randomized, double-blind, placebo-controlled multicentre study (CHRONOS). A total of 740 subjects were treated up to 52 weeks. The study population had a mean age of 37.1 years, 39.7% was female, 66.2% white, 27.2% Asian, 4.6% black, and reported co-morbid atopic conditions such as asthma (39.3%), allergic rhinitis (42.8%), food allergy (33.4%), and allergic conjunctivitis (23.2%).

In the monotherapy studies, the proportion of subjects who discontinued treatment due to adverse events was 1.9% of the placebo group and 1.9% of the DUPIXENT 300 mg every other week (Q2W) group.

In the concomitant TCS study, the proportion of subjects who discontinued treatment due to adverse events was 7.6% of the placebo + TCS group and 1.8% of the DUPIXENT 300 mg Q2W + TCS group.

Table 1 summarizes the adverse reactions that occurred in ≥1% of subjects treated with DUPIXENT during the first 16-weeks of treatment in placebo-controlled trials.
### Table 1 - Adverse Reactions Occurring in ≥1% of subjects with Atopic Dermatitis Treated with DUPIXENT through Week 16 in Placebo-Controlled Trials

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>DUPIXENT Monotherapy a</th>
<th>DUPIXENT + TCS b</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo N=517 n (%)</td>
<td>Placebo +TCS N=315 n (%)</td>
</tr>
<tr>
<td>Injection site reaction</td>
<td>28 (5.4%)</td>
<td>51 (9.6%)</td>
</tr>
<tr>
<td>Conjunctivitis^c</td>
<td>12(2.3%)</td>
<td>51(9.6%)</td>
</tr>
<tr>
<td>Blepharitis</td>
<td>1 (0.2%)</td>
<td>2 (0.4%)</td>
</tr>
<tr>
<td>Oral herpes</td>
<td>8 (1.5%)</td>
<td>20 (3.8%)</td>
</tr>
<tr>
<td>Eye pruritus</td>
<td>1 (0.2%)</td>
<td>3 (0.6%)</td>
</tr>
<tr>
<td>Dry eye</td>
<td>0</td>
<td>1 (0.2%)</td>
</tr>
<tr>
<td>Herpes simplex^d</td>
<td>4 (0.8%)</td>
<td>9 (1.7%)</td>
</tr>
<tr>
<td>Keratitis^e</td>
<td>0</td>
<td>1 (0.2%)</td>
</tr>
<tr>
<td>Eosinophilia</td>
<td>2 (0.4%)</td>
<td>9 (1.7%)</td>
</tr>
</tbody>
</table>

^a Safety data from a phase 2, dose-ranging study and the SOLO 1 and SOLO 2 studies.

^b Safety data from the CHRONOS study. Subjects were on background TCS therapy.

^c Conjunctivitis cluster includes conjunctivitis, allergic conjunctivitis, bacterial conjunctivitis, viral conjunctivitis, giant papillary conjunctivitis, eye irritation, and eye inflammation.

^d In clinical trials, herpes simplex cases were mucocutaneous, generally mild to moderate in severity, and did not include eczema herpeticum. Eczema herpeticum cases were reported separately and incidence was lower in subjects treated with DUPIXENT compared to placebo.

^e Keratitis cluster includes keratitis, ulcerative keratitis, allergic keratitis, atopic keratoconjunctivitis, and ophthalmic herpes simplex.

Q2W: every other week; TCS: topical corticosteroids

The safety profile of DUPIXENT + TCS through week 52 was consistent with the safety profile observed at week 16.

**Adolescents**

The safety of DUPIXENT was assessed in a study of 250 subjects 12 to 17 years of age with moderate-to-severe atopic dermatitis (AD-1526). The safety profile of DUPIXENT in these subjects followed through Week 16 was consistent with the safety profile from studies in adults with atopic dermatitis.

The long-term safety of DUPIXENT was assessed in an open-label extension study in patients 12 to 17 years of age with moderate-to-severe atopic dermatitis (AD-1434). The safety profile of DUPIXENT in patients followed through Week 52 was similar to the safety profile observed at Week 16 in AD-1526 study. The long-term safety profile of DUPIXENT observed in adolescents was consistent with that seen in adults with atopic dermatitis.

**Asthma**

A total of 2888 adult and adolescent subjects with moderate-to-severe asthma were evaluated in 3 randomized, placebo-controlled, multicentre trials of 24 to 52 weeks duration.
(DRI12544, QUEST, and VENTURE). Of these, 2678 subjects had a history of 1 or more severe exacerbations in the year prior to enrollment despite regular use of medium- to high-dose inhaled corticosteroids plus an additional controller(s) (DRI12544 and QUEST), while 210 subjects were receiving high-dose inhaled corticosteroids plus up to two additional controllers along with maintenance oral corticosteroids (VENTURE). The safety population (DRI12544 and QUEST) had a mean age of 48.1 years, 63.4% were female, 81.9% were white, 12.5% Asian, 4.4% black, and 76.9% reported co-morbid atopic conditions such as, allergic rhinitis (67.5%), allergic conjunctivitis (14.5%), chronic rhinosinusitis (17.3%), nasal polyposis (12.3%), atopic dermatitis (9.7%), and food allergy (8.5%). DUPIXENT 200 mg or 300 mg was administered subcutaneously every-other-week, following an initial dose of 400 mg or 600 mg, respectively.

In DRI12544 and QUEST studies, the proportion of subjects who discontinued treatment due to an adverse event was 3.2% in the DUPIXENT 200 mg Q2W group, 6.1% in the DUPIXENT 300 mg Q2W group, and 4.3% in the combined placebo group.

**Error! Reference source not found.** summarizes the adverse reactions that occurred at a rate of at least 1% in subjects receiving DUPIXENT and at higher rate than in their respective comparator groups in DRI12544 and QUEST studies.

### Table 2: Adverse Reactions Occurring in ≥1% of the DUPIXENT Groups in DRI12544 and QUEST and Greater than Placebo (6 Month Safety Pool)

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>DRI12544 and QUEST</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DUPIXENT 200 mg Q2W</td>
</tr>
<tr>
<td></td>
<td>N=779 n (%)</td>
</tr>
<tr>
<td>Injection site reactions&lt;sup&gt;a&lt;/sup&gt;</td>
<td>111 (14%)</td>
</tr>
<tr>
<td>Oropharyngeal pain</td>
<td>13 (2%)</td>
</tr>
<tr>
<td>Eosinophilia&lt;sup&gt;b&lt;/sup&gt;</td>
<td>17 (2%)</td>
</tr>
</tbody>
</table>

<sup>a</sup> Injection site reactions cluster includes erythema, edema, pruritus, pain, and inflammation.

<sup>b</sup> Eosinophilia = blood eosinophils ≥3,000 cells/mcL, or deemed by the investigator to be an adverse event. None met the criteria for serious eosinophilic conditions *(see Warnings and Precautions)*.

### Chronic Rhinosinusitis with Nasal Polyposis

A total of 722 adult subjects with chronic rhinosinusitis with nasal polyposis (CRSwNP) were evaluated in 2 randomized, placebo-controlled, multicentre trials of 24 to 52 weeks duration (SINUS-24 and SINUS-52) The safety pool consisted of data from the first 24 weeks of treatment.

In the safety pool, the proportion of subjects who discontinued treatment due to adverse events was 2.0% of the DUPIXENT 300 mg Q2W group and 4.6% of the placebo group. Table 3 summarizes the adverse reactions that occurred at a rate of at least 1% in subjects treated with DUPIXENT and at a higher rate than in their respective comparator group in SINUS-24 and SINUS-52.

### Table 2: Adverse Reactions Occurring in ≥1% of the DUPIXENT Group in SINUS-24
and SINUS-52 and at a greater frequency than Placebo (24-Week Safety Pool)

<table>
<thead>
<tr>
<th>Adverse Reaction</th>
<th>SINUS-24 and SINUS-52</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>DUPIXENT 300 mg Q2W</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N=440</td>
<td>N=282</td>
</tr>
<tr>
<td></td>
<td>n (%)</td>
<td>n (%)</td>
</tr>
<tr>
<td>Injection site reactions(^a)</td>
<td>28 (6.4%)</td>
<td>12 (4.3%)</td>
</tr>
<tr>
<td>Conjunctivitis(^b)</td>
<td>7 (1.6%)</td>
<td>2 (0.7%)</td>
</tr>
<tr>
<td>Arthralgia</td>
<td>14 (3.2%)</td>
<td>5 (1.8%)</td>
</tr>
<tr>
<td>Gastritis</td>
<td>7 (1.6%)</td>
<td>2 (0.7%)</td>
</tr>
<tr>
<td>Insomnia</td>
<td>6 (1.4%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Eosinophilia</td>
<td>5 (1.1%)</td>
<td>1 (0.4%)</td>
</tr>
</tbody>
</table>

\(^a\) Injection site reactions cluster includes injection site reactions, pain, bruising, and swelling.

\(^b\) Conjunctivitis cluster includes conjunctivitis, allergic conjunctivitis, bacterial conjunctivitis, viral conjunctivitis, giant papillary conjunctivitis, eye irritation, and eye inflammation.

The safety profile of DUPIXENT through Week 52 was generally consistent with the safety profile observed at Week 24.

**Description of Selected Adverse Reactions**

**Hypersensitivity**

Hypersensitivity reactions, including anaphylaxis and serum sickness or serum sickness-like reactions, have been reported in subjects receiving DUPIXENT (see WARNINGS AND PRECAUTIONS, Immune).

One serious case of anaphylaxis has been reported in the asthma development program following administration of DUPIXENT (see WARNINGS AND PRECAUTIONS, Immune).

**Eosinophils**

Subjects receiving DUPIXENT had a greater mean initial increase from baseline in blood eosinophil count compared to subjects receiving placebo. Blood eosinophil counts declined to near baseline levels during study treatment.

Across all indications, the incidence of treatment-emergent eosinophilia (≥500 cells/mcL) was consistent in DUPIXENT and placebo groups. Treatment-emergent eosinophilia (≥5,000 cells/mcL) was reported in <2% of subjects receiving DUPIXENT and <0.5% in subjects receiving placebo.

**Infections**

In atopic dermatitis, asthma, and CRSwNP, the rate of serious infections was consistent between subjects receiving DUPIXENT- and subjects receiving placebo.

The overall incidence of infections or serious infections was consistent with DUPIXENT compared to placebo in the primary safety pool for atopic dermatitis clinical studies. In the 16-week monotherapy clinical studies, serious infections were reported in 1.0% of subjects treated with placebo and 0.5% of subjects treated with DUPIXENT. In the 52-week CHRONOS trial, serious infections were reported in 0.6% of subjects treated with placebo.
and 0.2% of subjects treated with DUPIXENT.

The overall incidence of infections was consistent with DUPIXENT compared to placebo in the safety pool for asthma clinical studies. In the 24-week safety pool, serious infections were reported in 1.0% of subjects receiving DUPIXENT and 1.1% of subjects receiving placebo. In the 52-week QUEST study, serious infections were reported in 1.3% of subjects receiving DUPIXENT and 1.4% of subjects receiving placebo.

The overall incidence of infections was consistent with DUPIXENT compared to placebo in the safety pool for CRSwNP clinical studies. In the 24-week safety pool, serious infections were reported in 0.7% of subjects receiving DUPIXENT and 1.1% of subjects receiving placebo. In the 52-week SINUS-52 study, serious infections were reported in 1.3% of subjects receiving DUPIXENT and 1.3% of subjects receiving placebo.

**Eczema Herpeticum and Herpes Zoster**

The rate of eczema herpeticum was consistent in the DUPIXENT and placebo groups in 16 week monotherapy studies. In the 52-week placebo-controlled CHRONOS trial, the incidence of eczema herpeticum in the DUPIXENT combined group was 0.2% and in the placebo group was 1.9%.

Herpes zoster was reported in <0.1% of the DUPIXENT groups (<1%) and in <1% of the placebo group (1 per 100 subject-years) in the 16-week monotherapy trials. In the 52-week DUPIXENT + TCS trial, herpes zoster was reported in 1% of the DUPIXENT + TCS group (1 per 100 subject-years) and 2% of the placebo + TCS group (2 per 100 subject-years).

**Conjunctivitis**

During the 52-week treatment period of concomitant therapy trial (CHRONOS) in subjects with atopic dermatitis, conjunctivitis was reported in 16% of the DUPIXENT 300 mg Q2W + TCS group (20 per 100 subject-years) and in 9% of the placebo + TCS group (10 per 100 subject-years). During the 52-week treatment period of subjects with CRSwNP (SINUS-52), conjunctivitis was reported in 3% of subjects receiving DUPIXENT and in 1% of subjects receiving placebo.

**Immunogenicity**

As with all therapeutic proteins, there is a potential for immunogenicity with dupilumab.

Approximately 5% of subjects with atopic dermatitis, asthma or CRSwNP who received DUPIXENT 300 mg Q2W for 52 weeks developed anti-drug antibodies (ADA) to dupilumab; approximately 2% exhibited persistent ADA responses and approximately 2% had neutralizing antibodies.

Approximately 9% of subjects with asthma who received DUPIXENT 200 mg Q2W for 52 weeks developed antibodies to dupilumab; approximately 4% exhibited persistent ADA responses and approximately 4% had neutralizing antibodies.

Approximately 4% of subjects with atopic dermatitis, asthma or CRSwNP in the placebo groups in the 52 week studies were positive for antibodies to DUPIXENT; approximately 2%
exhibited persistent ADA responses and approximately 1% had neutralizing antibodies.

ADA responses were not generally associated with impact on DUPIXENT exposure, safety, or efficacy. Less than 1% of subjects exhibited high titer ADA responses associated with reduced exposure and efficacy. Two subjects who experienced high titer antibody responses developed serum sickness or serum sickness-like reactions during treatment with DUPIXENT (see WARNINGS AND PRECAUTIONS, Immune).

The observed incidence of persistent ADA responses and neutralizing activity in the assay are highly dependent on the sensitivity and specificity of the assay used. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease status of the individual patient. For these reasons, comparison of the incidence of antibodies to DUPIXENT with the incidence of antibodies to other products may be misleading.

Post-Market Adverse Drug Reactions

The following additional adverse reactions have been identified during post-approval use of DUPIXENT.

• Immune system disorders:
  Angioedema

• Musculoskeletal and connective tissue disorders:
  Arthralgia

DRUG INTERACTIONS

Interactions with CYP450 Substrates
In a clinical trial with 12-13 evaluable subjects with atopic dermatitis, the effects of dupilumab injection on the pharmacokinetics of caffeine (metabolized by CYP1A2), warfarin (metabolized by CYP2C9), omeprazole (metabolized by CYP2C19), metoprolol (metabolized by CYP2D6), and midazolam (metabolized by CYP3A4) were evaluated. The AUC of metoprolol increased by 29% after dupilumab injection administration (a SC loading dose of 600 mg followed by 300 mg SC weekly for 6 weeks). The AUC of other CYP substrates investigated were comparable before and after dupilumab injection administration.

Use with Other Drugs for Treatment of Asthma
An effect of dupilumab on the pharmacokinetics of co-administered medications is not expected. Based on the population analysis, commonly co-administered medications had no effect on dupilumab pharmacokinetics in subjects with moderate to severe asthma.

Drug-Vaccine Interactions

Live Vaccines
DUPIXENT has not been studied with live vaccines. Live vaccines should not be given concurrently with DUPIXENT.

Non-Live Vaccines
Immune responses to vaccination were assessed in a study in which subjects with atopic dermatitis were treated once weekly for 16 weeks with 300 mg of dupilumab injection. After 12 weeks of dupilumab injection administration, subjects were vaccinated with a Tdap vaccine (T cell-dependent, Adacel®) and a meningococcal polysaccharide vaccine (T cell-independent, Menomune®) and immune responses were assessed 4 weeks later. Antibody responses to both tetanus vaccine and meningococcal polysaccharide vaccine were similar in dupilumab injection-treated and placebo-treated subjects. No adverse interactions between either of the non-live vaccines and dupilumab injection were noted in the study.

**DOSAGE AND ADMINISTRATION**

**Recommended Dose and Dosage Adjustment**

DUPIXENT is administered by subcutaneous injection.

**Atopic Dermatitis**

**Adults**

The recommended dose of DUPIXENT for adult patients with atopic dermatitis is an initial dose of 600 mg (two 300 mg injections), followed by 300 mg every other week.

**Adolescents**

The recommended dose of DUPIXENT for adolescent patients 12 to 17 years of age is specified in Table 4.

<table>
<thead>
<tr>
<th>Body Weight of Patient</th>
<th>Initial Dose</th>
<th>Subsequent Doses (every other week)</th>
</tr>
</thead>
<tbody>
<tr>
<td>less than 60 kg</td>
<td>400 mg (two 200 mg injections)</td>
<td>200 mg</td>
</tr>
<tr>
<td>60 kg or more</td>
<td>600 mg (two 300 mg injections)</td>
<td>300 mg</td>
</tr>
</tbody>
</table>

DUPIXENT can be used with or without topical corticosteroids. Topical calcineurin inhibitors may be used, but should be reserved for problem areas only, such as the face, neck, intertriginous and genital areas.

**Asthma**

The recommended dose of DUPIXENT for adults and adolescents (12 years of age and older) is:

- An initial dose of 400 mg (two 200 mg injections) followed by 200 mg given every other week for patients with severe asthma with a type 2/eosinophilic phenotype. The dose may be increased to 300 mg every-other-week based on clinical judgement.
- An initial dose of 600 mg (two 300 mg injections) followed by 300 mg given every-other-week for patients with oral corticosteroids-dependent asthma or with
co-morbid moderate-to-severe atopic dermatitis or adults with co-morbid severe chronic rhinosinusitis with nasal polyposis for which DUPIXENT is indicated.

**Chronic Rhinosinusitis with Nasal Polyps**
The recommended dose of DUPIXENT for adult patients with chronic rhinosinusitis with nasal polyps is 300 mg every-other-week.

**Missed Dose**

If a dose is missed, instruct the patient to administer the injection within 7 days from the missed dose and then resume the patient's original schedule. If the missed dose is not administered within 7 days, instruct the patient to wait until the next dose on the original schedule.

**Administration**

For atopic dermatitis patients receiving an initial 600 mg dose, administer two 300 mg DUPIXENT injections consecutively in different injection sites.

For the initial 400 mg dose, administer two 200 mg DUPIXENT injections consecutively in different injection sites.

DUPIXENT is intended for use under the guidance of a healthcare professional. A patient may self-inject DUPIXENT or the patient's caregiver may administer DUPIXENT. Provide proper training to patients and/or caregivers on the preparation and administration of DUPIXENT prior to use according to the Instructions for Use (IFU).

DUPIXENT is self-administered by subcutaneous injection into the thigh or abdomen, except for the 5 cm (2 inches) around the navel, using a single-use pre-filled syringe or pen. If a caregiver administers DUPIXENT, an injection, in the upper arm can also be used.

It is recommended to rotate the injection site with each injection.

DUPIXENT should not be injected into skin that is tender, damaged or has bruises or scars.

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

**Special populations**

**Pediatrics (≥12 years of age):**

**Atopic Dermatitis**

Efficacy and safety of DUPIXENT in pediatric patients with atopic dermatitis below the age of 12 years have not been established.
Asthma
Efficacy and safety of DUPIXENT in pediatric patients with asthma below the age of 12 years have not been established.

Chronic Rhinosinusitis with Nasal Polyps
Efficacy and safety of DUPIXENT in pediatric patients with CRSwNP have not been established.

Geriatrics (>65 years of age):
No dose adjustment is recommended for elderly patients (see ACTIONS AND CLINICAL PHARMACOLOGY, Special Populations and Conditions).

Hepatic impairment
No data are available in patients with hepatic impairment (see ACTIONS AND CLINICAL PHARMACOLOGY, Special Populations and Conditions).

Renal impairment
No dosage adjustment is recommended in patients with mild or moderate renal impairment. No data are available in patients with severe renal impairment (see ACTIONS AND CLINICAL PHARMACOLOGY, Special Populations and Conditions).

Body weight
No dose adjustment for body weight is recommended in adult patients with atopic dermatitis (see ACTIONS AND CLINICAL PHARMACOLOGY, Special Populations and Conditions).

For patients 12 to 17 years of age with atopic dermatitis, the recommended every other week dose is 200 mg (<60 kg) or 300 mg (≥60 kg) (see DOSAGE AND ADMINISTRATION, Recommended Dose and Dosage Adjustment).

OVERDOSAGE
In clinical studies, no safety issues were identified with single intravenous doses up to 12 mg/kg.

There is no specific treatment for DUPIXENT overdose. In the event of overdose, monitor the patient for any signs or symptoms of adverse reactions and institute appropriate symptomatic treatment immediately.

For management of a suspected drug overdose, contact your regional Poison Control Centre.

ACTION AND CLINICAL PHARMACOLOGY

Mechanism of Action
Dupilumab is a recombinant human IgG4 monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling by specifically binding to the IL-4Rα subunit.
shared by the IL-4 and IL-13 receptor complexes. Dupilumab inhibits IL-4 signaling via the Type I receptor (IL-4Rα/γc), and both IL-4 and IL-13 signaling through the Type II receptor (IL-4Rα/IL-13Rα).

IL-4 and IL-13 are key type 2 (including Th2) cytokines involved in atopic disease.

Type 2 inflammation is an important component in the pathogenesis of asthma, atopic dermatitis, and CRSwNP. Multiple cell types that express IL-4Rα (e.g., mast cells, eosinophils, macrophages, lymphocytes, epithelial cells, goblet cells) and inflammatory mediators (e.g., histamine, eicosanoids, leukotrienes, cytokines, chemokines) are involved in inflammation. Blocking IL-4Rα with dupilumab inhibits IL-4 and IL-13 cytokine-induced inflammatory responses, including the release of pro-inflammatory cytokines, chemokines, nitric oxide, and IgE; however, the mechanism of dupilumab action in asthma has not been definitively established.

**Pharmacodynamics**

**Atopic Dermatitis**

In clinical trials that enrolled subjects with atopic dermatitis, treatment with DUPIXENT was associated with decreases from baseline in concentrations of type 2-associated biomarkers, such as thymus and activation-regulated chemokine (TARC/CCL17), total serum IgE, and allergen-specific IgE in serum. A reduction of lactate dehydrogenase (LDH), a biomarker associated with AD disease activity and severity, was observed with DUPIXENT treatment.

DUPIXENT suppressed TARC relative to placebo as early as week 2, with a trend of continued decline to a maximal and sustained suppression by Week 12. The majority of subjects treated with DUPIXENT in the CHRONOS study (87.0% and 84.9% of subjects in the DUPIXENT 300 mg Q2W and 300 mg QW, respectively) achieved normalized TARC levels compared to 20.0% in the placebo group at week 52.

Total IgE was reduced -74.8% and -73.9% by Week 52 (median change from baseline) with DUPIXENT 300 mg Q2W and 300 mg QW, respectively compared to a 0% reduction in the placebo group. Consistent trends were observed for allergen specific IgEs. After 52 weeks of treatment, total IgE was normalized in 11.7% and 15.9% of subjects receiving DUPIXENT 300 mg Q2W and 300 mg QW, respectively compared to 4.4% in the placebo group. Consistent trends were observed with antigen-specific IgEs, including S. aureus specific enterotoxin A, grass and tree allergens.

**Asthma**

Consistent with inhibition of IL-4 and IL-13 signaling, dupilumab decreased FeNO and circulating concentrations of eotaxin-3, total IgE, allergen specific IgE, TARC, and periostin relative to placebo, in subjects with severe asthma. These reductions in biomarkers of inflammation were consistent for the 200 mg Q2W and 300 mg Q2W regimens, with near maximal reduction observed after 2 weeks of exposure to dupilumab, except for IgE, which declined more slowly. These reductions in biomarkers were sustained throughout treatment.
Pharmacokinetics

The pharmacokinetics of dupilumab injection are consistent in subjects with atopic dermatitis, asthma, and CRSwNP.

**Absorption:**
After a single subcutaneous (SC) dose of 75-600 mg dupilumab injection, median times to maximum concentration in serum (t_{max}) were 3-7 days. The absolute bioavailability of dupilumab injection following a SC dose is consistent between AD, asthma, and CRSwNP patients, ranging from 61% and 64%, as determined by a population pharmacokinetic (PK) analysis.

Administration of a single loading dose of 600 mg on Day 1 leads to rapid attainment of clinically effective concentrations within 2 weeks.

For every-other-week dosing (Q2W) with either 200 mg or 300 mg, starting with a respective loading dose of 400 mg or 600 mg, or with 300 mg without a loading dose, population PK analysis determined steady-state concentrations to be achieved by 16 weeks. Mean steady-state trough concentration were 39 mg/L at 200 mg Q2W and 73 mg/L at 300 mg Q2W.

For weekly dosing (QW) with 300 mg, starting with a loading dose of 600 mg, population PK analysis determined steady state concentrations to be achieved after 13 weeks in a typical patient. Mean steady state trough concentration was 189 mg/L.

**Dose Linearity**
Due to nonlinear clearance, dupilumab exposure, as measured by area under the concentration-time curve, increases with dose in a greater than proportional manner following single SC doses from 75 - 600 mg.

**Distribution:**
A volume of distribution for dupilumab of approximately 4.6 L was estimated by population PK analysis, indicating that dupilumab is distributed primarily in the vascular system.

**Metabolism:**
Specific metabolism studies were not conducted because dupilumab is a protein. Dupilumab is expected to degrade to small peptides and individual amino acids.

**Excretion:**
Dupilumab elimination is mediated by parallel linear and nonlinear pathways. At higher concentrations, dupilumab elimination is primarily through a non-saturable proteolytic pathway, while at lower concentrations, the non-linear saturable IL-4Ra target-mediated elimination predominates.

After the last steady state dose, the median time for dupilumab concentrations to decrease below the lower limit of detection, determined by population PK analysis, was 9 weeks for 200 mg Q2W, 10-11 weeks for the 300 mg Q2W regimen and 13 weeks for the 300 mg QW regimen.
Special Populations and Conditions

**Pediatrics:**

*Atopic Dermatitis*
For adolescents 12 to 17 years of age subjects with atopic dermatitis received every other week dosing (Q2W) with either 200 mg (<60 kg) or 300 mg (≥60 kg), mean±SD steady state trough concentration was 54.5±27.0 mg/L.

The pharmacokinetics of dupilumab in pediatric patients (<12 years of age) with atopic dermatitis have not been fully established.

*Asthma*
A total of 107 adolescents aged 12 to 17 years with moderate to severe asthma were enrolled in QUEST study and received either 200 mg (n=21) or 300 mg (n=18) DUPIXENT (or matching placebo either 200 mg [n=34] or 300 mg [n=34]) every-other-week. The mean ±SD steady-state trough concentration of dupilumab was 46.7±26.9 mcg/mL or 107±51.6 mcg/mL, respectively, for 200 mg or 300 mg administered every-other-week.

**Geriatrics:**

*Atopic Dermatitis*
In subjects with atopic dermatitis who were 65 years and older, the mean steady-state trough concentrations of dupilumab were 69.4 mg/L and 166 mg/L, respectively, for 300 mg administered every 2 weeks and weekly. No dose adjustment in this population is recommended.

*Asthma*
Of the 1977 subjects with asthma exposed to DUPIXENT, a total of 240 subjects were 65 years or older and 39 subjects were 75 years or older. Efficacy and safety in this age group was consistent with the overall study population.

**Age:**
Age was not found to be associated with any clinically meaningful impact on the systemic exposure of DUPIXENT determined by population PK analysis.

**Gender:**
Gender was not found to be associated with any clinically meaningful impact on the systemic exposure of DUPIXENT determined by population PK analysis.

**Race:**
Race was not found to be associated with any clinically meaningful impact on the systemic exposure of DUPIXENT by population PK analysis.

**Hepatic Impairment:**
Dupilumab, as a monoclonal antibody, is not expected to undergo significant hepatic elimination. No clinical studies have been conducted to evaluate the effect of hepatic impairment on the pharmacokinetics of dupilumab.
Renal Impairment:
Dupilumab, as a monoclonal antibody, is not expected to undergo significant renal elimination. No clinical studies have been conducted to evaluate the effect of renal impairment on the pharmacokinetics of dupilumab. Population PK analysis did not identify mild or moderate renal impairment as having a clinically meaningful influence on the systemic exposure of DUPIXENT. No data are available in patients with severe renal impairment.

Body weight:
No dose adjustment for body weight is recommended in adult patients with atopic dermatitis.

For patients 12 to 17 years of age with atopic dermatitis, the recommended every other week dose is 200 mg (<60 kg) or 300 mg (≥60 kg) (see DOSAGE AND ADMINISTRATION, Recommended Dose and Dosage Adjustment).

STORAGE AND STABILITY
Store refrigerated at 2°C to 8°C in the original carton to protect from light.

Do not freeze.

Do not expose to heat.

Do not shake.

Do not use beyond the expiry date stamped on the carton and container label.

SPECIAL HANDLING INSTRUCTIONS
The patient may either self-inject DUPIXENT, or a caregiver may administer DUPIXENT, after guidance has been provided by a healthcare professional on proper subcutaneous injection technique.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. If the solution is discolored or contains visible particulate matter, the solution should not be used.

The 300 mg pre-filled syringe with a needle shield, pre-filled syringe or pre-filled pen should be allowed to reach room temperature by waiting for 45 min before injecting DUPIXENT.

The 200 mg pre-filled syringe with a needle shield should be allowed to reach room temperature by waiting for 30 min before injecting DUPIXENT.

If necessary, pre-filled syringes or pens may be kept at room temperature up to 25°C for a maximum of 14 days. Do not store above 25°C. After removal from the refrigerator, DUPIXENT must be used within 14 days or discarded.

The pre-filled syringe or pen should not be exposed to heat or direct sunlight.
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
DOSAGE FORMS, COMPOSITION AND PACKAGING

DUPIXENT is supplied as a clear to slightly opalescent, colorless to pale yellow sterile, preservative-free, solution, which is free from visible particulates.

DUPIXENT 300 mg is available in a single-use pre-filled syringe with needle shield (PFS-S), a single-use pre-filled syringe (PFS) or pre-filled pen (PFP), designed to deliver 300 mg dupilumab in 2 mL solution (150 mg/mL) via subcutaneous injection.

DUPIXENT 200 mg is available in a single-use pre-filled syringe with needle shield (PFS-S), designed to deliver 200 mg dupilumab in 1.14 mL solution (175 mg/mL) via subcutaneous injection.

Non-medicinal ingredients: L-arginine hydrochloride, L-histidine, polysorbate 80, sodium acetate, sucrose, and water for injection, adjusted to pH 5.9 with acetic acid.

300 mg Pre-Filled Syringe with needle shield
- DUPIXENT® is provided as a single dose in a 2.25-mL siliconized clear Type-I glass pre-filled syringe with a fixed 27 gauge ½ inch, thin wall stainless steel staked needle and passive needle shield.
- The needle cap is not made with natural rubber latex.

300 mg Pre-filled Syringe
- DUPIXENT is provided as a single dose in a 2.25-mL siliconized clear Type-I glass pre-filled syringe with a fixed 27 gauge ½ inch, thin wall stainless steel staked needle.
- The needle cap is not made with natural rubber latex.

300 mg Pre-filled Pen
- DUPIXENT is provided as a single dose in a 2.25-mL siliconized clear Type-I glass syringe.
- The needle cap is not made with natural rubber latex.

200 mg Pre-Filled Syringe with needle shield
- DUPIXENT® is provided as a single dose in a 1.14-mL siliconized clear Type-I glass pre-filled syringe with a fixed 27 gauge ½ inch, thin wall stainless steel staked needle and passive needle shield.
- The needle cap is not made with natural rubber latex.

DUPIXENT is available in packs containing 1 or 2 pre-filled syringes with needle shield, or pre-filled syringes or pre-filled pens.
PART II: SCIENTIFIC INFORMATION

PHARMACEUTICAL INFORMATION

Drug Substance

DUPIXENT is a fully human IgG4 monoclonal antibody produced by recombinant DNA technology in Chinese Hamster Ovary cell suspension culture. Dupilumab is a covalent heterotetramer consisting of two disulfide-linked human heavy chains, each covalently linked through a disulfide bond to a human kappa light chain. There is a single N-linked glycosylation site in each heavy chain, located within the CH2 domain of the Fc constant region of the molecule. The DUPIXENT heavy chain has an immunoglobulin (Ig) G4P isotype constant region. IgG4P is an IgG4 constant region with a single amino acid substitution in the hinge region that recreates the IgG1 hinge sequence in order to stabilize IgG4 dimer formation. The variable domains of the heavy and light chains combine to form the IL-4Rα binding site within the antibody.

Dupilumab has a molecular weight of approximately 147 kDa.
CLINICAL TRIALS

Atopic Dermatitis in Adults
Study demographics and trial design

Three randomized, double-blind, placebo-controlled trials (SOLO 1, SOLO 2, and CHRONOS) enrolled a total of 2119 subjects 18 years of age and older with moderate-to-severe atopic dermatitis (AD) not adequately controlled by topical medication(s). Disease severity was defined by an Investigator’s Global Assessment (IGA) score ≥3 in the overall assessment of AD lesions on a severity scale of 0 to 4, an Eczema Area and Severity Index (EASI) score ≥16 on a scale of 0 to 72, and a minimum body surface area involvement of ≥10%. At baseline, 59% of subjects were male, 67% were white, 52% of subjects had a baseline IGA score of 3 (moderate AD), and 48% of subjects had a baseline IGA of 4 (severe AD). The baseline mean EASI score was 33 and the baseline weekly averaged peak pruritus Numeric Rating Scale (NRS) was 7 on a scale of 0-10.

In all three trials, subjects in the DUPIXENT group received subcutaneous injections of DUPIXENT 600 mg at Week 0, followed by 300 mg every other week (Q2W). In the monotherapy trials (SOLO 1 and SOLO 2), subjects received DUPIXENT or placebo for 16 weeks.

In the concomitant therapy trial (CHRONOS), subjects received DUPIXENT or placebo with concomitant topical corticosteroids (TCS) and as needed topical calcineurin inhibitors for problem areas only, such as the face, neck, intertriginous and genital areas for 52 weeks.

All three trials assessed the primary endpoint, the change from baseline to Week 16 in the proportion of subjects with an IGA 0 (clear) or 1 (almost clear) and at least a 2-point improvement. Other endpoints included the proportion of subjects with EASI-75 (improvement of at least 75% in EASI score from baseline), and reduction in itch as defined by at least a 4-point improvement in the peak pruritus NRS from baseline to Week 16.

Table 3 - Summary of demographics for clinical trials in subjects with moderate-to-severe atopic dermatitis (AD)

<table>
<thead>
<tr>
<th>Study #</th>
<th>Trial design</th>
<th>Dosage, route of administration and duration</th>
<th>Study subjects (n = number)</th>
<th>Mean age (Range)</th>
<th>Gender</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOLO 1</td>
<td>Randomized, double-blind, placebo-controlled, parallel group, in adults with moderate-to-severe AD</td>
<td>Subcutaneous: dupilumab injection vs. placebo - Dupilumab injection: 600 mg loading dose, then 300 mg Q2W or 300 mg QW - Placebo 16 weeks</td>
<td>Dupilumab injection: - 300 mg Q2W: n = 224 - 300 mg QW: n = 223 Placebo: n = 224</td>
<td>39.5 (18-85)</td>
<td>M: 58.1% F: 41.9%</td>
</tr>
<tr>
<td>Study #</td>
<td>Trial design</td>
<td>Dosage, route of administration and duration</td>
<td>Study subjects (n = number)</td>
<td>Mean age (Range)</td>
<td>Gender</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------------------------</td>
<td>---------------------------------------------</td>
<td>-----------------------------</td>
<td>------------------</td>
<td>----------------</td>
</tr>
</tbody>
</table>
| SOLO 2 | Randomized, double-blind, placebo-controlled, parallel group, in adults with moderate-to-severe AD | Subcutaneous: dupilumab injection vs. placebo  
  - Dupilumab injection: 600 mg loading dose, then 300 mg Q2W or 300 mg QW  
  - Placebo  
  16 weeks                                                                 | Dupilumab injection:  
  - 300 mg Q2W: n = 233  
  - 300 mg QW: n = 239  
  Placebo: n = 236 | 37.1 (18-88) | M: 57.6%  
  F: 42.4% |
| CHRONOS | Randomized, double-blind, placebo-controlled, parallel group, in adults with moderate-to-severe AD | Dupilumab injection + topical corticosteroids (TCS) vs. placebo+TCS*  
  Subcutaneous:  
  - Dupilumab injection: 600 mg loading dose, then 300 mg Q2W or 300 mg QW  
  - Placebo  
  52 weeks                                                                 | Dupilumab injection:  
  - 300 mg Q2W: n = 106  
  - 300 mg QW: n = 319  
  Placebo: n = 315 | 37.1 (18-81) | M: 60.3%  
  F: 39.7% |

* Subjects received DUPIXENT or placebo with concomitant use of TCS starting at baseline using a standardized regimen. Subjects were also permitted to use topical calcineurin inhibitors (TCI)  
Q2W: every other week; QW: weekly
Study results

Clinical response at Week 16 (Trials SOLO 1, SOLO 2, and CHRONOS)

In SOLO 1, SOLO 2 and CHRONOS, from baseline to week 16, a clinically and significantly greater proportion of subjects randomized to DUPIXENT achieved an IGA 0 or 1 response, EASI-75, and/or an improvement of ≥4 points on the pruritus NRS compared to placebo (see Table 5).

Table 5: Efficacy Results of DUPIXENT Monotherapy and concomitant TCS\(^{f}\) at Week 16 (FAS)

<table>
<thead>
<tr>
<th>Subjects randomized</th>
<th>SOLO 1 (FAS)(^{a})</th>
<th>SOLO 2 (FAS)(^{a})</th>
<th>CHRONOS (FAS)(^{f})</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo</td>
<td>DUPIXENT 300 mg Q2W</td>
<td>Placebo</td>
</tr>
<tr>
<td>Subjects randomized</td>
<td>224</td>
<td>224</td>
<td>236</td>
</tr>
<tr>
<td>IGA 0 or 1(^{b}),</td>
<td>10.3 %</td>
<td>37.9 %(^{e})</td>
<td>8.5 %</td>
</tr>
<tr>
<td>% responders(^{c})</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EASI-75, % responders(^{c})</td>
<td>14.7 %</td>
<td>51.3 %(^{e})</td>
<td>11.9 %</td>
</tr>
<tr>
<td>EASI-90, % responders(^{c})</td>
<td>7.6 %</td>
<td>35.7 %(^{e})</td>
<td>7.2 %(^{e})</td>
</tr>
<tr>
<td>Number of subjects</td>
<td>212</td>
<td>213</td>
<td>221</td>
</tr>
<tr>
<td>with baseline pruritus</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NRS score ≥4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pruritus NRS</td>
<td>12.3 %</td>
<td>40.8 %(^{e})</td>
<td>9.5 %</td>
</tr>
<tr>
<td>(≥4-point improvement),</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>% responders(^{c, d})</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

IGA = Investigator’s Global Assessment scale; EASI = Eczema Area and Severity Index; NRS = pruritus Numerical Rating Scale; Q2W = every other week

\(^{a}\) Full analysis set (FAS) includes all subjects randomized.

\(^{b}\) Responder was defined as a patient with IGA 0 or 1 (“clear” or “almost clear”) with a reduction of ≥ 2 points on a 0-4 IGA scale.

\(^{c}\) Subjects who received rescue treatment or with missing data were considered as non-responders.

\(^{d}\) A significantly greater proportion of patients on DUPIXENT had improvement in pruritus NRS of ≥ 4 points compared to placebo at week 2 (p<0.01)

\(^{e}\) p-value <0.0001

\(^{f}\) All patients were on background TCS therapy and subjects were permitted to use topical calcineurin inhibitors.

A significantly greater proportion of subjects randomized to DUPIXENT achieved a rapid improvement in the pruritus NRS compared to placebo (defined as ≥4-point improvement as
early as week 2; p<0.01) and the proportion of subjects responding on the pruritus NRS continued to increase through the treatment period (see Figure 1).

**Figure 1 - Proportion of subjects with ≥ 4-point Improvement on the Pruritus NRS in SOLO 1<sup>a</sup> and SOLO 2<sup>b</sup> (FAS)**

![Figure 1](image)

<sup>a</sup>In the primary analyses of the efficacy endpoints, subjects who received rescue treatment or with missing data were considered non-responders.

<sup>b</sup>Full Analysis Set (FAS) includes all subjects randomized.

Treatment effects in subgroups (weight, age, gender, race, and background treatment, including immunosuppressants) in SOLO 1 and SOLO 2 were in general consistent with the results in the overall study population.

In studies SOLO 1, SOLO 2, and CHRONOS, a third randomized treatment arm of DUPIXENT 300 mg QW did not demonstrate additional treatment benefit over DUPIXENT 300 mg Q2W.

### 52-Week Concomitant TCS Study (CHRONOS)

In the CHRONOS trial, of the 421 subjects, 353 had been on study for 52 weeks at the time of data analysis. Of these 353 subjects, responders at Week 52 represent a mixture of subjects who maintained their efficacy from Week 16 (e.g., 53% of DUPIXENT IGA 0 or 1 responders at Week 16 remained responders at Week 52) and subjects who were non-responders at Week 16 who later responded to treatment. Results of supportive analyses of the 353 subjects in the CHRONOS trial are presented in Table 7.
### Table 7 - The Percentage of Responders in Clinical Trial CHRONOS by Treatment Arm and Responder Status at Week 16 and Week 52

<table>
<thead>
<tr>
<th></th>
<th>DUPIXENT 300 mg Q2W + TCS</th>
<th>Placebo + TCS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Subjects&lt;sup&gt;a&lt;/sup&gt;</td>
<td>89</td>
<td>264</td>
</tr>
<tr>
<td>Responder&lt;sup&gt;b,c&lt;/sup&gt; at Week 16 and 52</td>
<td>22%</td>
<td>7%</td>
</tr>
<tr>
<td>Responder at Week 16 but Non-responder at Week 52</td>
<td>20%</td>
<td>7%</td>
</tr>
<tr>
<td>Non-responder at Week 16 and Responder at Week 52</td>
<td>13%</td>
<td>6%</td>
</tr>
<tr>
<td>Non-responder at Week 16 and 52</td>
<td>44%</td>
<td>80%</td>
</tr>
<tr>
<td>Overall Responder&lt;sup&gt;b,c&lt;/sup&gt; Rate at Week 52</td>
<td>36%</td>
<td>13%</td>
</tr>
</tbody>
</table>

<sup>a</sup> In CHRONOS, of the 421 randomized and treated subjects, 68 subjects (16%) had not been on study for 52 weeks at the time of data analysis.

<sup>b</sup> Responder was defined as a subject with IGA 0 or 1 (“clear” or “almost clear”) with a reduction of ≥2 points on a 0-4 IGA scale.

<sup>c</sup> Subjects who received rescue treatment or with missing data were considered as non-responders.

### Additional Secondary Endpoints

Patient reported outcomes in both monotherapy studies (SOLO1 and SOLO2) and in the DUPIXENT + TCS study (CHRONOS) were consistent with significant improvements observed in the physician reported outcomes.

A larger proportion of subjects treated with DUPIXENT had ≥4 points improvement (corresponding to minimal clinically important difference) in POEM and DLQI in SOLO1, SOLO2, and CHRONOS studies compared to placebo.

In SOLO 1, the proportion of DUPIXENT-treated responders for POEM and DLQI was 67.6% and 64.1%, respectively, compared to 26.9% and 30.5% for placebo at week 16.

In SOLO 2, the proportion of DUPIXENT-treated responders for POEM and DLQI was 71.7% and 73.1%, respectively, compared to 24.4% and 27.6% for placebo at week 16.

In CHRONOS, the proportion of DUPIXENT-treated responders for POEM and DLQI was 76.4% and 80.0%, respectively, compared to 26.1% and 30.3% for placebo at week 52.

### Atopic Dermatitis in Adolescents

DUPIXENT monotherapy in adolescent subjects was evaluated in a multicenter, randomized, double-blind, placebo-controlled trial, AD-1526, in 251 adolescent subjects 12 to 17 years of age with moderate-to-severe AD defined by IGA score ≥3 in the overall assessment of AD lesions on a severity scale of 0 to 4, an EASI score ≥16 on a scale of 0 to 72, and a minimum BSA involvement of ≥10%. Eligible subjects enrolled into this trial had previous inadequate response to topical medication.
Subjects in the DUPIXENT group received an initial dose of 400 mg at Week 0, followed by 200 mg Q2W for subjects with baseline weight of <60 kg or an initial dose of 600 mg at Week 0, followed by 300 mg Q2W for subjects with baseline weight of ≥60 kg for 16 weeks. DUPIXENT was administered by subcutaneous injection. If needed to control intolerable symptoms, subjects were permitted to receive rescue treatment at the discretion of the investigator. Subjects who received rescue treatment were considered non-responders.

In the AD-1526 study, the mean age was 14.5 years, the median weight was 59.4 kg, 41% of subjects were female, 63% were White, 15% were Asian, and 12% were Black. At baseline 46% of subjects had an IGA score of 3 (moderate AD), 54% had an IGA score of 4 (severe AD), the mean BSA involvement was 57%, and 42% had received prior systemic immunosuppressants. Also, at baseline the mean EASI score was 36, and the weekly averaged peak pruritus NRS was 8 on a scale of 0-10. Overall, 92% of subjects had at least one co-morbid allergic condition; 66% had allergic rhinitis, 54% had asthma, and 61% had food allergies.

The co-primary endpoints were the proportion of subjects with IGA 0 (clear) or 1 (almost clear) with at least a 2-point improvement, and the proportion of subjects with EASI-75 (improvement of at least 75% in EASI), from baseline to Week 16. Other evaluated outcomes included the proportion of subjects with EASI-90 (improvement of at least 90% in EASI from baseline), reduction in itch as measured by the peak pruritus NRS and from baseline to Week 16. Additional secondary endpoints included mean change from baseline to week 16 in the POEM and CDLQI scores.

The efficacy results at Week 16 for AD-1526 Study are presented in Table 8.

<table>
<thead>
<tr>
<th></th>
<th>Placebo N=85</th>
<th>DUPIXENT 200 mg (&lt;60 kg) or 300 mg (≥60 kg) Q2W N=82</th>
</tr>
</thead>
<tbody>
<tr>
<td>IGA 0 or 1(^{b,c})</td>
<td>2%</td>
<td>24%</td>
</tr>
<tr>
<td>EASI-75(^{c})</td>
<td>8%</td>
<td>42%</td>
</tr>
<tr>
<td>EASI-90(^{c})</td>
<td>2%</td>
<td>23%</td>
</tr>
<tr>
<td>Pruritus NRS, LS mean % change from baseline (+/- SE)</td>
<td>-19% (4.1)</td>
<td>-48% (3.4)</td>
</tr>
<tr>
<td>Peak Pruritus NRS (≥4-point improvement)(^{c})</td>
<td>5%</td>
<td>37%</td>
</tr>
</tbody>
</table>

\(^{a}\) Full Analysis Set (FAS) includes all subjects randomized.

\(^{b}\) Responder was defined as a subject with IGA 0 or 1 (“clear” or “almost clear”) with a reduction of ≥2 points on a 0-4 IGA scale.

\(^{c}\) Subjects who received rescue treatment or with missing data were considered as non-responders (59% and 21% in the placebo and DUPIXENT arms, respectively.

Patient reported outcomes CLDQI and POEM were consistent with significant improvements observed in the physician reported outcomes. The reductions in mean CDLQI and mean POEM scores from baseline to week 16 week were -8.5 (0.50) and -10.1 (0.76) for DUPIXENT and -5.1(0.62) and -3.8 (0.96) for placebo, respectively.

A larger percentage of subjects randomized to placebo needed rescue treatment (topical corticosteroids, systemic corticosteroids, or systemic non-steroidal immunosuppressants) as compared to the DUPIXENT group (59% and 21%, respectively).
A significantly greater proportion of subjects randomized to DUPIXENT achieved a rapid improvement in the pruritus NRS compared to placebo, (defined as ≥4-point improvement as early as Week 4; nominal p<0.001) and the proportion of subjects responding on the pruritus NRS continued to increase through the treatment period. The improvement in pruritus NRS occurred in conjunction with the improvement of objective signs of atopic dermatitis.

The long-term efficacy of DUPIXENT in adolescent patients with moderate-to-severe AD who had participated in previous clinical trials of DUPIXENT was assessed in an open-label extension trial (AD-1434). Efficacy data from this trial suggests that clinical benefit provided at Week 16 was sustained through Week 52.

Asthma

Study demographics and trial design

The asthma development program included three randomized, double-blind, placebo-controlled, parallel-group, multi-centre studies (DRI12544, QUEST, and VENTURE) of 24 to 52 weeks in treatment duration. Patients were enrolled without requiring a minimum baseline blood eosinophil or other type 2 inflammatory biomarkers (e.g. FeNO or IgE) level

DRI12544
DRI12544 was a 24-week dose-ranging study that included 776 subjects (18 years of age and older). DUPIXENT compared with placebo was evaluated in adult patients with asthma receiving medium-or-high dose inhaled corticosteroid and a long-acting beta agonist. Subjects were randomized to receive either 200 mg (n=150) or 300 mg (n=157) DUPIXENT every-other-week or 200 mg (n=154) or 300 mg (n=157) DUPIXENT every 4 weeks following an initial dose of 400 mg, 600 mg, or placebo (n=158), respectively. The primary analysis population was subjects with baseline blood eosinophil count of ≥300 cells/mcL. The primary endpoint was change from baseline to Week 12 in FEV1 (L). Annualized rate of severe asthma exacerbation events during the 24-week placebo controlled treatment period was also determined as described in QUEST.

QUEST
QUEST was a 52-week study that included 1902 subjects (12 years of age and older). DUPIXENT compared with placebo was evaluated in 107 adolescent and 1795 adult subjects with asthma receiving medium- or high- dose inhaled corticosteroid (ICS) and one or two additional controller medications (e.g., long-acting beta agonists). Subjects were randomized to receive either 200 mg (n=631) or 300 mg (n=633) DUPIXENT every-other-week (or matching placebo for either 200 mg [n = 317] or 300 mg [n= 321] every-other-week) following an initial dose of 400 mg, 600 mg, or placebo, respectively. The primary endpoints were the annualized rate of severe exacerbation events during the 52-week placebo-controlled period and change from baseline in pre-bronchodilator FEV1 at Week 12. A severe exacerbation was defined as a deterioration of asthma requiring the use of systemic corticosteroids for at least 3 days or hospitalization or emergency room visit due to asthma that required systemic corticosteroids.

VENTURE
VENTURE was a 24-week oral corticosteroid (OCS) reduction study in 210 subjects with asthma receiving high-dose inhaled corticosteroids plus additional controller(s) (e.g., LABA). All subjects were receiving OCS; the mean baseline daily OCS dose was 11 mg in subjects receiving DUPIXENT and 12 mg in subjects receiving placebo. The number of subjects receiving 5 mg OCS as the optimized OCS dose at randomization was limited to approximately 30% of the study population. After optimizing the OCS dose during the screening period, subjects were randomized to receive 300 mg DUPIXENT (n=103) or placebo (n=107) once every-other-week for 24 weeks following an initial dose of 600 mg or placebo. Subjects continued to receive their existing asthma medicine during the study; however, their OCS dose was reduced every 4 weeks during the OCS reduction phase (Week 4-20), if asthma control was maintained. Asthma control was maintained if subjects did not experience i) an increase in ACQ-5 ≥ 0.5 units, ii) a severe asthma exacerbations, or iii) a clinically significant event that required OCS dose adjustment. The primary endpoint was the percent reduction of OCS dose at Weeks 20 to 24 compared with the baseline dose, while maintaining asthma control.

The demographics and baseline characteristics of these 3 trials are provided in Table 4.

**Table 4: Demographics and Baseline Characteristics of Asthma Trials**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>DRI12544 (n = 776)</th>
<th>QUEST (n = 1902)</th>
<th>VENTURE (n=210)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (years) (SD)</td>
<td>48.6 (13.0)</td>
<td>47.9 (15.3)</td>
<td>51.3 (12.6)</td>
</tr>
<tr>
<td>% Female</td>
<td>63.1</td>
<td>62.9</td>
<td>60.5</td>
</tr>
<tr>
<td>% White</td>
<td>78.2</td>
<td>82.9</td>
<td>93.8</td>
</tr>
<tr>
<td>Duration of Asthma (years), mean (± SD)</td>
<td>22.03 (15.42)</td>
<td>20.94 (15.36)</td>
<td>19.95 (13.90)</td>
</tr>
<tr>
<td>Never smoked, (%)</td>
<td>77.4</td>
<td>80.7</td>
<td>80.5</td>
</tr>
<tr>
<td>Mean exacerbations in previous year (± SD)</td>
<td>2.17 (2.14)</td>
<td>2.09 (2.15)</td>
<td>2.09 (2.16)</td>
</tr>
<tr>
<td>High dose ICS use (%)</td>
<td>49.5</td>
<td>51.5</td>
<td>88.6</td>
</tr>
<tr>
<td>Pre-dose FEV1 (L) at baseline (± SD)</td>
<td>1.84 (0.54)</td>
<td>1.78 (0.60)</td>
<td>1.58 (0.57)</td>
</tr>
<tr>
<td>Mean percent predicted FEV1 (%)(±SD)</td>
<td>60.77 (10.72)</td>
<td>58.43 (13.52)</td>
<td>52.18 (15.18)</td>
</tr>
<tr>
<td>% Reversibility (± SD)</td>
<td>26.85 (15.43)</td>
<td>26.29 (21.73)</td>
<td>19.47 (23.25)</td>
</tr>
<tr>
<td>Mean ACQ-5 score (± SD)</td>
<td>2.74 (0.81)</td>
<td>2.76 (0.77)</td>
<td>2.50 (1.16)</td>
</tr>
<tr>
<td>Mean AQLQ score (± SD)</td>
<td>4.02 (1.09)</td>
<td>4.29 (1.05)</td>
<td>4.35 (1.17)</td>
</tr>
<tr>
<td>Atopic Medical History % Overall (AD %, NP %, AR %)</td>
<td>72.9 (8.0, 10.6, 61.7)</td>
<td>77.7 (10.3, 12.7, 68.6)</td>
<td>72.4 (7.6, 21.0, 55.7)</td>
</tr>
<tr>
<td>Mean FeNO ppb (± SD)</td>
<td>39.10 (35.09)</td>
<td>34.97 (32.85)</td>
<td>37.61 (31.38)</td>
</tr>
<tr>
<td>Mean total IgE IU/mL (± SD)</td>
<td>435.05 (753.88)</td>
<td>432.40 (746.66)</td>
<td>430.58 (775.96)</td>
</tr>
<tr>
<td>Mean blood eosinophil count (± SD) cells/mlL</td>
<td>350 (430)</td>
<td>360 (370)</td>
<td>350 (310)</td>
</tr>
</tbody>
</table>

ICS = inhaled corticosteroid; LABA = Long-acting beta2-agonist; FEV1 = Forced expiratory volume in 1 second; ACQ-5 = Asthma Control Questionnaire-5; AQLQs = Asthma Quality of Life Questionnaire, Standardized Version; AD = atopic dermatitis; NP = nasal polyposis; AR = allergic rhinitis; FeNO = fraction of exhaled nitric oxide.
Study Results

Exacerbations

Results of annualized rate of severe exacerbation event for DRI12544 and QUEST are presented in Table 10. In the overall population, in QUEST, the rate of severe exacerbations was 0.46 and 0.52 for DUPIXENT 200 mg Q2W and 300 mg Q2W, respectively, compared to matched placebo rates of 0.87 and 0.97. The rate ratio of severe exacerbations compared to placebo was 0.52 (95% CI: 0.41, 0.66) and 0.54 (95% CI: 0.43, 0.68) for DUPIXENT 200 mg Q2W and 300 mg Q2W, respectively.

Table 10: Rate of Severe Exacerbations in DRI12544 and QUEST

<table>
<thead>
<tr>
<th>Study</th>
<th>Treatment</th>
<th>Baseline Blood EOS ≥300 cells/mL</th>
<th>N</th>
<th>Rate (95% CI)</th>
<th>Rate Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DRI12544</td>
<td>DUPIXENT 200 mg Q2W</td>
<td>65</td>
<td></td>
<td>0.30</td>
<td>(0.13, 0.68)</td>
</tr>
<tr>
<td>DRI12544</td>
<td>DUPIXENT 300 mg Q2W</td>
<td>64</td>
<td></td>
<td>0.20</td>
<td>(0.08, 0.52)</td>
</tr>
<tr>
<td>DRI12544</td>
<td>Placebo</td>
<td>68</td>
<td></td>
<td>1.04</td>
<td>(0.57, 1.90)</td>
</tr>
<tr>
<td>QUEST</td>
<td>DUPIXENT 200 mg Q2W</td>
<td>264</td>
<td></td>
<td>0.37</td>
<td>(0.29, 0.48)</td>
</tr>
<tr>
<td>QUEST</td>
<td>Placebo</td>
<td>148</td>
<td></td>
<td>1.08</td>
<td>(0.85, 1.38)</td>
</tr>
<tr>
<td>QUEST</td>
<td>DUPIXENT 300 mg Q2W</td>
<td>277</td>
<td></td>
<td>0.40</td>
<td>(0.32, 0.51)</td>
</tr>
<tr>
<td>QUEST</td>
<td>Placebo</td>
<td>142</td>
<td></td>
<td>1.24</td>
<td>(0.97, 1.57)</td>
</tr>
</tbody>
</table>

<sup>a</sup>p-value <0.0001

For QUEST study, a hierarchical testing procedure was used to strongly control the overall Type I error rate. Adjusted annualized severe exacerbation event rate is derived using negative binomial model with the total number of events as the response variable, with treatment, age, region, baseline eosinophil stratum, baseline ICS dose level and number of severe exacerbation events within 1 year prior to the study as covariates, and log-transformed standardized observation duration as an offset variable.

Results of annualized rate of severe exacerbation event based on baseline blood eosinophil counts are presented in Figure 2. Results of annualized rate of severe exacerbation event based on an exploratory analysis by baseline FeNO levels are presented in Figure 3.
Figure 2. Relative Risk in Annualized Event Rate of Severe Exacerbations Across Baseline Blood Eosinophil Count (cells/mcL) in QUEST

<table>
<thead>
<tr>
<th>Baseline blood eosinophil group (cells/mcL)</th>
<th>DUPIXENT(n)</th>
<th>Placebo(n)</th>
<th>Rate Ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Overall</td>
<td>633</td>
<td>321</td>
<td>0.54 (0.43, 0.68)</td>
</tr>
<tr>
<td></td>
<td>631</td>
<td>317</td>
<td>0.52 (0.41, 0.66)</td>
</tr>
<tr>
<td>≥500</td>
<td>141</td>
<td>74</td>
<td>0.29 (0.18, 0.45)</td>
</tr>
<tr>
<td></td>
<td>145</td>
<td>76</td>
<td>0.26 (0.16, 0.40)</td>
</tr>
<tr>
<td>≥300 – &lt;500</td>
<td>136</td>
<td>68</td>
<td>0.37 (0.22, 0.60)</td>
</tr>
<tr>
<td></td>
<td>119</td>
<td>72</td>
<td>0.50 (0.29, 0.84)</td>
</tr>
<tr>
<td>≥150 – &lt;300</td>
<td>175</td>
<td>95</td>
<td>0.56 (0.35, 0.89)</td>
</tr>
<tr>
<td></td>
<td>173</td>
<td>84</td>
<td>0.64 (0.41, 1.02)</td>
</tr>
<tr>
<td>&lt;150</td>
<td>181</td>
<td>83</td>
<td>1.15 (0.75, 1.77)</td>
</tr>
<tr>
<td></td>
<td>193</td>
<td>85</td>
<td>0.92 (0.58, 1.47)</td>
</tr>
</tbody>
</table>
In QUEST, the estimated rate ratio of exacerbations leading to hospitalizations and/or emergency room visits versus placebo was 0.53 (95% CI: 0.28, 1.03) and 0.74 (95% CI: 0.32, 1.70) with DUPIXENT 200 mg or 300 mg Q2W, respectively.

**Lung Function**
Results of change from baseline in pre-bronchodilator FEV1 at Week 12 for DRI12544 and QUEST are presented in Table 12. In the overall population in QUEST, the FEV1 LS mean change from baseline was 0.32 L (21%) and 0.34 L (23%) for DUPIXENT 200 mg Q2W and 300 mg Q2W, respectively, compared to matched placebo means of 0.18 L (12%) and 0.21 L (14%). The LS mean treatment difference versus placebo was 0.14 L (95% CI: 0.08, 0.19) and 0.13 L (95% CI: 0.08, 0.18) for DUPIXENT 200 mg Q2W and 300 mg Q2W, respectively.
<table>
<thead>
<tr>
<th>Study</th>
<th>Treatment</th>
<th>Baseline Blood EOS ≥300 cells/mL</th>
<th>N</th>
<th>LS Mean Change from baseline L (%)</th>
<th>LS Mean Difference vs. placebo (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>DRI12544</td>
<td>DUPIXENT 200 mg Q2W</td>
<td>65</td>
<td>0.43 (25.9)</td>
<td>0.26</td>
<td>(0.11, 0.40)</td>
</tr>
<tr>
<td></td>
<td>DUPIXENT 300 mg Q2W</td>
<td>64</td>
<td>0.39 (25.8)</td>
<td>0.21</td>
<td>(0.06, 0.36)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>68</td>
<td>0.18 (10.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>QUEST</td>
<td>DUPIXENT 200 mg Q2W</td>
<td>264</td>
<td>0.43 (29.0)</td>
<td>0.21</td>
<td>(0.13, 0.29)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>148</td>
<td>0.21 (15.6)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>DUPIXENT 300 mg Q2W</td>
<td>277</td>
<td>0.47 (32.5)</td>
<td>0.24&lt;sup&gt;a&lt;/sup&gt;</td>
<td>(0.16, 0.32)</td>
</tr>
<tr>
<td></td>
<td>Placebo</td>
<td>142</td>
<td>0.22 (14.4)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<sup>a</sup>p-value <0.0001

For QUEST study, a hierarchical testing procedure was used to strongly control the overall Type I error rate. LS mean and LS mean difference were derived from MMRM model with change from baseline in pre-bronchodilator FEV1 values up to Week 12 as response variable, and treatment, age, sex, baseline height, region, baseline eosinophil stratum, baseline ICS dose level, visit, treatment by-visit interaction, baseline pre-bronchodilator FEV1 value and baseline-by-visit interaction as covariates.
Results of change from baseline in pre-bronchodilator FEV₁ at Week 12 based on baseline blood eosinophil counts are presented in Figure 4. Results of change from baseline in pre-bronchodilator FEV₁ at Week 12 based on an exploratory analysis by baseline FeNO levels are presented in Figure 5.

**Figure 4: LS Mean Difference in Change from Baseline vs Placebo to Week 12 in Pre-Bronchodilator FEV₁ across Baseline Blood Eosinophil Counts (cells/mcL) in QUEST**

**Figure 5: LS Mean Difference in Change from Baseline vs Placebo to Week 12 in Pre-Bronchodilator FEV₁ across Baseline FeNO (ppb) in QUEST**

The change in FEV₁ over 52 weeks in QUEST overall population is presented in Figure 6.
Figure 6: Mean Change from Baseline in Pre-Bronchodilator FEV$_1$ (L) Over Time in QUEST (ITT Population)

Asthma Symptoms and Quality of Life

ACQ-5 and AQLQ(S) were assessed in QUEST at 52 weeks. A responder rate was defined as an improvement in score of at least 0.5 units for ACQ-5 (scale range 0-6) and AQLQ(S) (scale range 1-7), respectively.

In QUEST, in the overall population, the ACQ-5 responder rate in subjects receiving DUPIXENT 200 mg and 300 mg Q2W was 69% and 69%, respectively, and 62% and 63% in subjects receiving placebo. The AQLQ(S) responder rate in subjects receiving DUPIXENT 200 mg and 300 mg Q2W was 62% and 62%, respectively, and 54% and 57% in subjects receiving placebo. The ACQ-5 and AQLQ(S) responder rates in subjects with baseline blood eosinophils $\geq$300 cells/mcL were consistent with the overall population.

Oral Corticosteroid Reduction (VENTURE)

The mean percent reduction in daily OCS dose from baseline at week 24 in subjects receiving the recommended dose of DUPIXENT was 70.1% (median 100 %) and placebo was 41.9% (median 50 %). Reductions of 50% or higher in the OCS dose were observed in 82 (79.6%) subjects receiving DUPIXENT and 57 (53.3%) of subjects receiving placebo. The proportion of subjects with a mean final OCS dose less than 5 mg at Weeks 24 was 69% for DUPIXENT and 33% for placebo. Only subjects with a daily baseline OCS dose of 30 mg or less were eligible to achieve a 100% reduction in OCS dose during the study. Of those subjects, 52.8% (54 of 103) receiving DUPIXENT and 29.2% (31 of 106) receiving placebo achieved a 100% reduction in OCS dose.
The annualized rate of severe exacerbation event was 0.65 in subjects receiving DUPIXENT and 1.60 in subjects receiving placebo; an exacerbation was defined as an increase in OCS dose for ≥3 days. The LS mean change from baseline in pre-bronchodilator FEV1 at week 24 was 0.22L in subjects receiving DUPIXENT and 0.01L in subjects receiving placebo. Changes in ACQ-5 and AQLQ(S) were consistent with those observed in QUEST.

**Chronic Rhinosinusitis with Nasal Polyps**

**Study demographics and trial design**

The chronic rhinosinusitis with nasal polyps (CRSwNP) development program included two randomized, double-blind, parallel-group, multicentre, placebo-controlled trials (SINUS-24 and SINUS-52) in 724 subjects aged 18 years and older receiving background intranasal corticosteroids (INCS). These trials included subjects with severe CRSwNP despite prior sinonasal surgery, treatment with systemic corticosteroids in the past 2 years, or who were ineligible to receive systemic corticosteroids. Subjects with chronic rhinosinusitis without nasal polyposis were not included in these trials. Rescue treatment with systemic corticosteroids or surgery was allowed during the trials at the investigator’s discretion. In SINUS-24, a total of 276 subjects were randomized to receive either 300 mg DUPIXENT (N=143) or placebo (N=133) every-other-week for 24 weeks. In SINUS-52, 448 subjects were randomized to receive either 300 mg DUPIXENT (N=150) every-other-week for 52 weeks, 300 mg DUPIXENT (N=145) every-other-week until week 24 followed by 300 mg DUPIXENT every 4 weeks until week 52, or placebo (N=153). All subjects had evidence of sinus opacification on the Lund MacKay (LMK) sinus CT scan and 73% to 90% of subjects had opacification of all sinuses. Subjects were stratified based on their histories of prior surgery and co-morbid asthma/nonsteroidal anti-inflammatory drug exacerbated respiratory disease (NSAID-ERD). A total of 63% of subjects reported previous sinus surgery, with a mean number of 2.0 prior surgeries, 74% used systemic corticosteroids in the previous 2 years with a mean number of 1.6 systemic corticosteroid courses in the previous 2 years, 59% had co-morbid asthma, and 28% had NSAID-ERD.

The co-primary efficacy endpoints were change from baseline to week 24 in bilateral endoscopic nasal polyps score (NPS; 0-8 scale) as graded by central blinded readers, and change from baseline to week 24 in nasal congestion/obstruction score averaged over 28 days (NC; 0-3 scale), as determined by subjects using a daily diary. For NPS, polyps on each side of the nose were graded on a categorical scale (0=no polyps; 1=small polyps in the middle meatus not reaching below the inferior border of the middle turbinate; 2=polyps reaching below the lower border of the middle turbinate; 3=large polyps reaching below the lower border of the inferior turbinate or polyps medial to the middle turbinate; 4=large polyps causing complete obstruction of the inferior nasal cavity). The total score was the sum of the right and left scores. NC was rated daily by the subjects on a 0 to 3 categorical intensity scale (0=no symptoms; 1=mild symptoms; 2=moderate symptoms; 3=severe symptoms).

In both trials, key secondary endpoints at week 24 included change from baseline in: LMK sinus CT scan score, University of Pennsylvania smell identification test (UPSIT), daily loss of smell, and 22-item sinal-nasal outcome test (SNOT-22). The LMK sinus CT scan score evaluated the
opacification of each sinus using a 0 to 2 scale (0=normal; 1=partial opacification; 2=total opacification) deriving a maximum score of 12 per side and a total maximum score of 24 (higher scores indicate more opacification). Olfactory function was assessed by UPSIT, which is a 40-odorant test (score range 0-40) used to distinguish subjects (mild [score of 31-34], moderate [score of 26-30], severe microsmia [score of 19-25]) or anosmia [score of 0-18]). Loss of smell was scored reflectively by the patient every morning on a 0-3 scale (0=no symptoms, 1=mild symptoms, 2=moderate symptoms, 3=severe symptoms). SNOT-22 includes 22 items assessing symptoms and symptom impact associated with CRSwNP with each item scored from 0 (no problem) to 5 (problem as bad as it can be) with a global score ranging from 0 to 110; SNOT-22 had a 2 week recall period. In the pool of the two trials, the reduction in the proportion of subjects requiring rescue treatment with systemic corticosteroid and/or sino-nasal surgery was evaluated.

Demographics and baseline characteristics of these 2 trials are provided in Table 12.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>SINUS-24 (N=276)</th>
<th>SINUS-52 (N=448)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age (years) (SD)</td>
<td>50.49 (13.39)</td>
<td>51.95 (12.45)</td>
</tr>
<tr>
<td>% Male</td>
<td>57.2</td>
<td>62.3</td>
</tr>
<tr>
<td>Mean CRSwNP duration (years)(SD)</td>
<td>11.11 (9.16)</td>
<td>10.94 (9.63)</td>
</tr>
<tr>
<td>Subjects with ≥ 1 prior surgery (%)</td>
<td>71.7</td>
<td>58.3</td>
</tr>
<tr>
<td>Subjects with systemic corticosteroid use in the previous 2 years (%)</td>
<td>64.9</td>
<td>80.1</td>
</tr>
<tr>
<td>Mean Bilateral endoscopic NPS (SD), range 0–8</td>
<td>5.75 (1.28)</td>
<td>6.10 (1.21)</td>
</tr>
<tr>
<td>Mean Nasal congestion (NC) score (SD) range 0–3</td>
<td>2.35 (0.57)</td>
<td>2.43 (0.59)</td>
</tr>
<tr>
<td>Mean LMK sinus CT total score (SD), range 0–24</td>
<td>19.03 (4.44)</td>
<td>17.96 (3.76)</td>
</tr>
<tr>
<td>Mean Smell test (UPSIT) score (SD), range 0–40</td>
<td>14.56 (8.48)</td>
<td>13.61 (8.02)</td>
</tr>
<tr>
<td>Mean Sense of smell loss score (AM), (SD) range 0–3</td>
<td>2.71 (0.54)</td>
<td>2.75 (0.52)</td>
</tr>
<tr>
<td>Mean SNOT-22 total score (SD), range 0–110</td>
<td>49.40 (20.20)</td>
<td>51.86 (20.90)</td>
</tr>
<tr>
<td>Mean blood eosinophils (cells/mcL)(SD)</td>
<td>437 (333)</td>
<td>431 (353)</td>
</tr>
<tr>
<td>Mean total IgE IU/mL (SD)</td>
<td>201.37 (281.50)</td>
<td>211.79 (257.38)</td>
</tr>
<tr>
<td>Atopic (type 2 inflammatory disease) Medical History</td>
<td>75.4%</td>
<td>82.4%</td>
</tr>
<tr>
<td>% Overall</td>
<td>75.4%</td>
<td>82.4%</td>
</tr>
<tr>
<td>Asthma (%)</td>
<td>58.3</td>
<td>59.6</td>
</tr>
<tr>
<td>NSAID-ERD (%)</td>
<td>30.4</td>
<td>26.8</td>
</tr>
</tbody>
</table>

Higher scores indicate greater disease severity except UPSIT where higher scores indicate lower disease severity; SD=standard deviation; AM = morning; NPS = nasal polyps score; LMK = Lund Mackay; UPSIT = University of Pennsylvania smell identification test; SNOT-22 = 22-item sino-nasal outcome test; NSAID-ERD= asthma/nonsteroidal anti-inflammatory drug exacerbated respiratory disease.
Clinical Response (SINUS-24 and SINUS-52)

The results for primary and key secondary endpoints in CRSwNP trials are presented in the Table 13.

Table 13: Results of the Primary and Key Secondary Endpoints at Week 24 in CRSwNP Trials

<table>
<thead>
<tr>
<th></th>
<th>SINUS -24</th>
<th>SINUS -52</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Placebo (n=133)</td>
<td>DUPIXENT 300mg Q2W (n=143)</td>
</tr>
<tr>
<td><strong>Primary Endpoints</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Scores</td>
<td>Baseline mean</td>
<td>LS mean change</td>
</tr>
<tr>
<td>NPS</td>
<td>5.86</td>
<td>0.17</td>
</tr>
<tr>
<td>NC</td>
<td>2.45</td>
<td>-0.45</td>
</tr>
<tr>
<td><strong>Key Secondary Endpoints</strong></td>
<td>Baseline mean</td>
<td>LS mean change</td>
</tr>
<tr>
<td>LMK sinus CT scan score</td>
<td>19.55</td>
<td>-0.74</td>
</tr>
<tr>
<td>UPSIT</td>
<td>14.44</td>
<td>0.70</td>
</tr>
<tr>
<td>Loss of smell</td>
<td>2.73</td>
<td>-0.29</td>
</tr>
<tr>
<td>SNOT-22</td>
<td>50.87</td>
<td>-9.31</td>
</tr>
</tbody>
</table>

NC = nasal congestion, NPS = nasal polyposis score; LMK = Lund-MacKay total CT score; UPSIT = University of Pennsylvania smell identification test; SNOT-22 = 22-item sino-nasal outcome test.

(all p values <0.0001). A hierarchical testing procedure was used to strongly control the overall Type I error rate in each study. Data collected after treatment discontinuation were included in the analyses. For subjects who underwent sino-nasal surgery or received systemic corticosteroids (SCS) for any reason, data collected post-surgery or post-SCS were not utilized, and the worst post-baseline value on or before the time of surgery or SCS was used in the analysis. Missing data were imputed by multiple imputation.

A reduction in score indicates improvement, except UPSIT where an increase indicates improvement.
The results of SINUS-52 trial at week 52 are presented in Table 14.

Table 14: Results of the efficacy at week 52 in SINUS-52 study

<table>
<thead>
<tr>
<th></th>
<th>Placebo (n=153)</th>
<th>DUPIXENT 300mg Q2W (n=150)</th>
<th>LS mean difference vs. Placebo (95%CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Baseline mean</td>
<td>LS mean change</td>
<td>Baseline mean</td>
</tr>
<tr>
<td>NPS</td>
<td>5.96</td>
<td>0.15</td>
<td>6.07</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NC</td>
<td>2.38</td>
<td>-0.37</td>
<td>2.48</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SNOT-22</td>
<td>53.48</td>
<td>-8.88</td>
<td>50.16</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

A reduction in score indicates improvement.

NC = nasal congestion, NPS = nasal polyposis score; SNOT-22 = 22-item sino-nasal outcome test. (all p values <0.0001). A hierarchical testing procedure was used to strongly control the overall Type I error rate in each study.

Data collected after treatment discontinuation were included in the analyses. For subjects who underwent sino-nasal surgery or received systemic corticosteroids (SCS) for any reason, data collected post-surgery or post-SCS were not utilized, and the worst post-baseline value on or before the time of surgery or SCS was used in the analysis. Missing data were imputed by multiple imputation.

Statistically significant differences were observed in SINUS-24 and SINUS-52 with regard to improvement in bilateral endoscopic NPS at Week 24 and at Week 52 in SINUS-52 following continuous treatment with DUPIXENT (Figure 7 and Figure 8). During the post-treatment period of SINUS-24 (e.g., Weeks 24-48) when subjects no longer received DUPIXENT, the treatment effect diminished over time (see Figure 7).
Figure 7 – LS mean change from baseline in bilateral nasal polyps score (NPS) up to Week 48 in SINUS-24 - ITT population.

![Graph showing LS mean change from baseline in bilateral nasal polyps score (NPS) up to Week 48 in SINUS-24 - ITT population.]

Figure 8 - LS mean change from baseline in bilateral nasal polyps score (NPS) up to Week 52 in SINUS-52 - ITT population.

![Graph showing LS mean change from baseline in bilateral nasal polyps score (NPS) up to Week 52 in SINUS-52 - ITT population.]

Statistically significant differences were observed in SINUS-24 and SINUS-52 with regard to improvement in NC at Week 24 and at Week 52 in SINUS-52 following continuous treatment with DUPIXENT (Figure 9 and Figure 10). During the post-treatment period of SINUS-24 (e.g., Weeks 24-48) when subjects no longer received DUPIXENT, the treatment effect diminished over time (see Figure 9).
Changes in LMK, UPSIT, and loss of smell scores at Week 52 were consistent with results observed at Week 24.

In the pre-specified multiplicity-adjusted pooled analysis of the two trials (up to Week 24 for SINUS-24 and up to Week 52 for SINUS-52), treatment with DUPIXENT resulted in significant reduction of systemic corticosteroid use or need for sino-nasal surgery (actual or planned) versus placebo (HR of 0.24; 95% CI: 0.17, 0.35) (see Figure 10).

In the pooled analysis, the proportion of subjects who required systemic corticosteroid use over the 52-week period was 12.3% in the DUPIXENT group and 38.0% in the placebo group. The
proportion of subjects who required sino-nasal surgery over the 52-week period was 1.2% in the DUPIXENT group and 10.2% in the placebo group.

**Figure 11** Kaplan Meier Curve for time-to-first systemic corticosteroid use or sino-nasal surgery during treatment period - ITT population [SINUS-24 and SINUS-52 pooled]

Changes in NPS, NC, and LMK scores in favour of dupilumab were consistent between subjects with CRSwNP with or without comorbid asthma.

In subjects with CRSwNP and co-morbid asthma, improvements in pre-bronchodilator FEV1 were consistent with those observed in the asthma program.
DETAILED PHARMACOLOGY

Dupilumab binds specifically to human IL-4Rα and does not react with any other animal species. Pivotal toxicology studies were therefore conducted using surrogate antibodies against the IL-4Rα of cynomolgus monkeys and CD-1 mice.

Animal Pharmacology

Dupilumab binds with high affinity to human IL-4Rα and inhibits both IL-4 and IL-13 mediated signaling in vitro and in vivo. Administration of dupilumab leads to a reduction in type 2 (including Th2) inflammation in different mouse models using mice that express human IL-4Rα and human IL-4. In the house dust mite (HDM) allergen inflammation model, dupilumab decreases circulating levels of IgE and allergen-specific IgG1, reduces pulmonary infiltration of eosinophils, and reduces goblet cell metaplasia in this model of type 2 (including Th2)-driven inflammation.

TOXICOLOGY

No significant adverse effects were observed in cynomolgus monkeys when administered a surrogate antibody against IL-4Rα by subcutaneous or intravenous injection up to dose levels of 100 mg/kg/week for 6 months (approximately 25-times the steady state exposure for the maximum recommended clinical dose). Serum drug levels achieved at these dosages were sufficient to have fully saturated the monkey IL-4Rα.

No juvenile toxicology studies have been conducted with dupilumab or any of its surrogates.

Carcinogenesis, Mutagenesis and Impairment of Fertility and Reproduction

Carcinogenicity studies have not been conducted with dupilumab.

No significant adverse embryofetal, morphological, functional or immunological developmental effects were observed in offspring of pregnant cynomolgus monkeys exposed to a surrogate antibody against IL-4Rα by subcutaneous injection from the beginning of organogenesis through parturition up to dose levels of 100 mg/kg/week. The overall rate of embryofetal loss during gestation was 5 of 20 (25%) in control animals, 10 of 20 (50%) in animals treated with 25 mg/kg/week, and 3 of 18 (17%) in animals treated with 100 mg/kg/week. Concentrations of the surrogate antibody observed in the infant monkeys at birth were comparable to those observed in maternal serum, indicating placental transfer.

No effects on fertility parameters, including reproductive organs, menstrual cycle length, or sperm analyses were observed in sexually mature mice receiving a murine surrogate antibody against IL-4Rα by subcutaneous injection up to dose levels of 200 mg/kg/week.
REFERENCES


READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

PART III: PATIENT MEDICATION INFORMATION

Pr DUPIXENT®

Dupilumab injection solution for subcutaneous injection

DUPIXENT 300 mg single-use syringe (300 mg/2 mL) in pre-filled syringe with or without needle shield or pre-filled pen

DUPIXENT 200 mg single-use syringe (200 mg/1.14 mL) in pre-filled syringe with needle shield

Read this carefully before you start taking DUPIXENT and each time you get a refill. This leaflet is a summary and will not tell you everything about this drug. Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about DUPIXENT.

What is DUPIXENT used for?

DUPIXENT is an injectable prescription medicine used:

Atopic Dermatitis

- To treat adults and adolescents (12 years and older) with moderate-to-severe atopic dermatitis, also known as atopic eczema. DUPIXENT can be used with or without topical corticosteroids.
- It is not known if DUPIXENT is safe and effective in children with atopic dermatitis below age of 12 years.

Asthma

- In addition to other asthma medicines for maintenance treatment of adults and adolescents (12 years and older) with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma, whose asthma is not controlled with their current asthma medicines. Severe eosinophilic asthma is a type of asthma where patients have increased eosinophils in the blood or lungs. Eosinophils are a type of white blood cell that are associated with inflammation of the airways that can cause your asthma to get worse or can increase the number of asthma attacks.
- It is not known if DUPIXENT is safe and effective in children with asthma below age of 12 years.
- DUPIXENT is not used to treat sudden breathing problems.

Chronic Rhinosinusitis with Nasal Polyposis

- Treat adult patients with severe chronic rhinosinusitis with nasal polyposis (CRSwNP) in
combination with intranasal corticosteroids, whose disease is not controlled with systemic corticosteroids or surgery.

- It is not known if DUPIXENT is safe and effective in children below age of 18 years.

**How does DUPIXENT work?**

DUPIXENT contains the active substance dupilumab.

Dupilumab is a monoclonal antibody (a type of specialized protein) that blocks the action of inflammatory proteins called IL-4 and IL-13. IL-4 and IL-13 contribute to signs and symptoms of atopic dermatitis, asthma, and CRSwNP.

Using DUPIXENT for atopic dermatitis can improve the condition of your skin and reducing itch.

Using DUPIXENT for severe eosinophilic asthma can reduce severe asthma attacks and improve your breathing. DUPIXENT may also help reduce the amount of another group of medicines you need to control your severe asthma, called oral corticosteroids, while reducing severe asthma attacks and improving your breathing.

Using DUPIXENT for CRSwNP can decrease the size of your nasal polyps, decrease your nasal congestion, and improve your sense of smell.

**What are the ingredients in DUPIXENT?**

Medicinal ingredients: dupilumab

Non-medicinal ingredients: acetic acid, L-arginine hydrochloride, L-histidine, polysorbate 80, sodium acetate, sucrose, water for injection.

**DUPIXENT comes in the following dosage forms:**

DUPIXENT comes as a single-dose (1 time use) pre-filled syringe with or without needle shield or pre-filled pen. Your healthcare provider will prescribe the type that is best for you.

**Do not use DUPIXENT if:**

Do not use DUPIXENT if you are allergic to dupilumab or to any of the ingredients in DUPIXENT.

DUPIXENT can potentially cause serious side effects, including generalized allergic (hypersensitivity) reactions and anaphylactic reaction. Check for signs or symptoms of these conditions (i.e. breathing problems, swelling of the face, lips, mouth, throat or tongue, fainting, dizziness, feeling lightheaded (low blood pressure), fever, general ill feeling, swollen lymph nodes, hives, itching, joint pain, skin rash) while you are taking DUPIXENT.
Stop taking DUPIXENT and tell your healthcare professional or seek medical help immediately if you experience any signs or symptoms of an allergic reaction (see also the table “Serious side effects and what to do about them” below).

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take DUPIXENT. Talk about any health conditions or problems you may have, including if you:

- have a parasitic (intestinal parasites) infection. DUPIXENT may weaken your resistance to infections caused by parasites. If you already have a parasitic infection, it should be treated before you start treatment with DUPIXENT. If you live in a region where these infections are common or if you are travelling to such a region, check with your doctor.
- are pregnant or plan to become pregnant. It is not known if DUPIXENT will harm your unborn baby. Tell your healthcare provider if you become pregnant while taking DUPIXENT.
- are breastfeeding or plan to breastfeed. You and your healthcare provider should decide if you will take DUPIXENT or breastfeed. You should not do both without talking to your healthcare provider first.
- have other allergic conditions such as asthma and are taking asthma medicines.
- are scheduled to receive a vaccination
- have eye problems (e.g., itching, redness)

Other warnings you should know about:
DUPIXENT is not a rescue medicine and should not be used to treat a sudden asthma attack.

Do not stop or reduce your asthma medicines, unless instructed by your healthcare professional. These medicines (especially ones called corticosteroids) must be stopped gradually, under the direct supervision of your healthcare professional. Rarely patients taking DUPIXENT may develop inflammation of blood vessels or lungs due to an increase of certain white blood cells (eosinophilia). This usually, but not always, happens in people who also take corticosteroids, which are being stopped or for which the dose is being lowered. Tell your healthcare professional immediately if you develop a combination of symptoms such as a persistent fever, shortness of breath, chest pain, rash, and/or pins and needles or numbness of arms or legs. There is no experience with DUPIXENT in children with atopic dermatitis less than 12 years of age. Therefore, the use of DUPIXENT is not recommended in this age group.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

The following may interact with DUPIXENT:

Inform your healthcare professional that you are taking DUPIXENT if you recently received a vaccine or if you are about to receive a vaccine. DUPIXENT should not be used at the same time with certain types of vaccines.
**How to take DUPIXENT:**

Always check the label of your pre-filled syringe or pen before each injection to make sure you have the correct product.

DUPIXENT should be allowed to reach room temperature by waiting for 45 minutes (for 300 mg pre-filled syringe or pen) and 30 minutes (for 200 mg pre-filled syringe) after removing from the refrigerator before injecting.

DUPIXENT is injected under the skin (subcutaneous use) of your upper leg (thigh), stomach area (abdomen, except 5 cm around your belly button); if somebody else gives you the injection, you can also use the upper arm. Choose a different spot each time you inject (e.g. right thigh then left thigh, or right abdomen then left abdomen). Do not inject into skin that is tender, damaged or has bruises or scars.

Do not inject DUPIXENT together with other injectable medicines at the same injection site.

It is important that you do not stop using DUPIXENT without talking with your healthcare provider. Prior to discontinuing DUPIXENT check with your healthcare professional if you need to adjust your treatment or need to manage other allergic and or atopic conditions.

Do not use DUPIXENT for a condition for which it was not prescribed. Do not give DUPIXENT to other people, even if they have the same signs or symptoms that you have. It may harm them.

**Learning how to use the pre-filled syringe (with or without needle shield) or pre-filled pen**

- Before you use the pre-filled syringe or pen for the first time, your healthcare professional will show you or your caregiver how to inject DUPIXENT. Do not try to inject DUPIXENT until you or your caregiver have been shown the correct way by your healthcare provider.
- Always read and use the pre-filled syringe or pen as described by the "Instructions for Use" provided in the box.

**Usual dose:**

Use DUPIXENT exactly as prescribed by your healthcare professional.

**Atopic Dermatitis**

**Recommended dose in adults**

In atopic dermatitis, the first time you use DUPIXENT you will receive 600 mg (two (2) injections under the skin (subcutaneous) of 300 mg each given in 2 different injection sites). Thereafter, DUPIXENT is given as a 300 mg injection once every other week.
Recommended dose in adolescents
The recommended dose of DUPIXENT for adolescents (12 to 17 years of age) with atopic dermatitis is based on body weight:

<table>
<thead>
<tr>
<th>Body Weight of Patient</th>
<th>Initial Dose</th>
<th>Subsequent Doses (every other week)</th>
</tr>
</thead>
<tbody>
<tr>
<td>less than 60 kg</td>
<td>400 mg (two 200 mg injections)</td>
<td>200 mg</td>
</tr>
<tr>
<td>60 kg or more</td>
<td>600 mg (two 300 mg injections)</td>
<td>300 mg</td>
</tr>
</tbody>
</table>

Asthma
In severe eosinophilic asthma, the recommended dose of DUPIXENT for adult and adolescents (12 years of age and older) is:
- A first dose of 400 mg (two (2) injections under the skin of 200 mg) followed by 200 mg every two weeks by injection. The dose may be increased to 300 mg every two weeks based on your healthcare professional’s assessment.

In severe asthma needing oral corticosteroids, the recommended dose of DUPIXENT for adults and adolescents (12 years of age and older) is:
- A first dose of 600 mg (two (2) injections under the skin of 300 mg) followed by 300 mg every two weeks by injection.

CRSwNP
In CRSwNP, DUPIXENT is given as a 300 mg subcutaneous injection once-every-other week.

Overdose:

If you think you have taken too much DUPIXENT, contact your healthcare professional, hospital emergency department or regional Poison Control Centre immediately, even if there are no symptoms.

Missed Dose:
If you miss a dose of DUPIXENT, give the injection within 7 days from the missed dose, and then continue with the original schedule. If the missed dose is not given within 7 days, wait until the next scheduled dose to give your DUPIXENT injection.

What are possible side effects from using DUPIXENT?
DUPIXENT may cause allergic reactions (hypersensitivity), including a severe reaction known as anaphylaxis. Stop using DUPIXENT and tell your healthcare professional or seek medical help immediately if you notice any signs or symptoms of an allergic reaction such as:
- breathing problems
- swelling of the face, lips, mouth, throat or tongue (angioedema)
- fever
- feeling ill
- swollen lymph nodes
- hives
- itching
- skin rash
- skin or eyelid itching
- joint pain
- fainting, dizziness, feeling lightheaded (low blood pressure)

DUPIXENT may cause eye problems, including eye pain or change in vision. Tell your healthcare professional if you have any new or worsening eye problems.

These are not all the possible side effects you may have when taking DUPIXENT. If you experience any side effects not listed here, contact your healthcare professional. Please also see “Do not use DUPIXENT if” section above.

The most common side effects of DUPIXENT include:
- injection site reactions
- eye and eyelid inflammation, including redness, swelling, itching, and/or dryness
- eye infections
- cold sores in your mouth or on your lips (oral herpes)
- extra high amount of a certain white blood cell (eosinophilia)
- trouble sleeping (insomnia)
- gastritis
- joint pain (arthralgia)
- headache

<table>
<thead>
<tr>
<th>Serious side effects and what to do about them</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Symptom / effect</strong></td>
</tr>
<tr>
<td><strong>UNCOMMON</strong></td>
</tr>
<tr>
<td>Allergic reactions (hypersensitivity)</td>
</tr>
</tbody>
</table>

If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.
Reporting Side Effects
You can help improve the safe use of health products for Canadians by reporting serious and unexpected side effects to Health Canada. Your report may help to identify new side effects and change the product safety information.

3 ways to report:

- Online at MedEffect;
- By calling 1-866-234-2345 (toll-free);
- By completing a Consumer Side Effect Reporting Form and sending it by:
  - Fax to 1-866-678-6789 (toll-free), or
  - Mail to: Canada Vigilance Program
    Health Canada, Postal Locator 1908C
    Ottawa, ON
    K1A 0K9
    Postage paid labels and the Consumer Side Effect Reporting Form are available at MedEffect.

NOTE: Contact your health professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

Keep out of reach and sight of children.

Do not use this medicine after the expiry date that is stated on the label and carton.

Store in a refrigerator (2°C - 8°C). Do not freeze.

Keep the syringe or pen in the outer carton to protect from light.

Do not expose to extreme heat.

DUPIXENT should be allowed to reach room temperature by waiting for 45 minutes (for 300 mg pre-filled syringe or pen) or 30 minutes (for 200 mg pre-filled syringe) after removing from the refrigerator before injecting.

If necessary, pre-filled syringes or pens may be kept at room temperature up to 25°C, away from direct heat and light, for a maximum of 14 days. Do not store above 25°C. After removal from the refrigerator, DUPIXENT must be used within 14 days or discarded.

Do not use this medicine if the solution is discolored or cloudy, or if it contains visible flakes or particles.

After use, put the syringe or pen into a puncture-resistant container. Always keep the container out of the reach of children. Ask your health care provider or pharmacist how to throw away the container. Do not recycle the container.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

**If you want more information about DUPIXENT:**

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes this Patient Medication Information by visiting the [Health Canada website](http://www.canada.ca); the manufacturer’s website [www.sanofi.ca](http://www.sanofi.ca), or by calling 1-800-589-6215.

This leaflet was prepared by sanofi-aventis Canada Inc.

DUPIXENT® is a registered trademark of Sanofi Biotechnology.

Last Revised:
INSTRUCTIONS FOR USE

DUPIXENT 300 MG SINGLE-DOSE PRE-FILLED SYRINGE WITH NEEDLE SHIELD

Read the Instructions for Use before using the DUPIXENT Pre-filled Syringe with needle shield.

This device is a Single-dose Pre-filled Syringe (called “Syringe” in these instructions) with a needle shield. It contains 300 mg of DUPIXENT for injection under the skin (subcutaneous injection).

Keep these instructions for future use. If you have any further questions, you should ask your healthcare provider or call 1-800-589-6215.

The parts of the DUPIXENT syringe are shown in this picture.
### Important Information

- **It is important that you do not try to give yourself or someone else the injection unless you have received training from your healthcare provider.**
- **Read all of the instructions carefully before using the Syringe.**
- **Ask your healthcare provider how often you will need to inject the medicine.**
- **Ask your healthcare provider to show you the right way to use the Syringe before you inject for the first time.**
- **Rotate the injection site each time you inject.**
- **To reduce the risk of accidental needle sticks, each pre-filled syringe has a needle shield that is automatically activated to cover the needle after you have given your injection.**
- **Do not use the Syringe if it has been dropped on a hard surface or damaged.**
- **Do not use the Syringe if the Needle Cap is missing or not securely attached.**
- **Do not touch the Plunger Rod until you are ready to inject.**
- **Do not inject through clothes.**
- **Do not get rid of any air bubbles in the Syringe.**
- **Do not pull back on the Plunger Rod at any time.**
- **Do not re-use the Syringe.**

### How to Store DUPIXENT:

- **Keep the Syringe(s) out of the reach of children.**
- **Keep unused Syringes in the original carton and store in the refrigerator between 2°C and 8°C.**
- **Remove the Syringe from the refrigerator at least 45 minutes before your injection so that it reaches room temperature.**
- **Do not keep DUPIXENT at room temperature for more than 14 days.**
- **Do not shake the Syringe at any time.**
- **Do not heat the Syringe.**
- **Do not freeze the Syringe.**
- **Do not put the Syringe into direct sunlight.**

### How to Dispose of (Throw Away) Used Syringes

Put your used Needles and Syringes in a puncture-resistant container right away after use.

> **Do not dispose of (throw away) the Syringes in your household trash.**

If you do not have a puncture-resistant container, you may use a household container that is:
- **made of a heavy-duty plastic;**
- **can be closed with a tightfitting, puncture-resistant lid, without sharps being able to come out,**
- **upright and stable during use,**
leak-resistant, and
properly labeled to warn of hazardous waste inside the container

When your puncture-resistant container is almost full, you will need to follow your provincial or local regulations for the correct way to dispose of it.

**Step 1: Remove**

Remove the Syringe from the carton by holding the middle of the Syringe Body:

⚠️ **Do not pull off the Needle Cap until you are ready to inject.**

⚠️ **Do not use the Syringe if it has been dropped on a hard surface or damaged.**

⚠️ **Do not keep DUPIXENT at room temperature for more than 14 days.**

---

**Step 2: Prepare**

Ensure you have the following:
- the DUPIXENT Pre-filled Syringe with needle shield
- 1 alcohol wipe*
- 1 cotton ball or gauze*
- a puncture-resistant container* (See Step 12)

*Items not included in the carton

Look at the label:
- Check the expiration date
- Check that you have the correct product and dose
Do not use the Syringe if the expiration date has passed.

Step 3: Inspect

Look at the medicine through the viewing window on the Syringe:

Check if the liquid is clear and colorless to pale yellow.

*Note: You may see an air bubble; this is normal.*

Do not use the Syringe if the liquid is discolored or cloudy, or if it contains visible flakes or particles.

Step 4: Wait 45 minutes

Lay the Syringe on a flat surface and let it naturally warm to room temperature for at least 45 minutes.

Do not heat the Syringe.

Do not put the Syringe into direct sunlight.

Do not keep DUPIXENT at room temperature for more than 14 days.
**Step 5: Select**

Select the injection site.
- You can inject into your thigh or abdomen, except for the 5 cm (2 inches) around your navel (belly-button).
- If somebody else gives you the injection, you can also use the upper arm.
- Change the injection site for each injection.

⚠️ **Do not inject into skin that is tender, damaged or has bruises or scars.**

**Step 6: Clean**

Wash your hands.
Clean the injection site with an alcohol wipe.

Let your skin dry before injecting.

⚠️ **Do not touch the injection site again or blow on it before the injection.**

---

**Step 7: Pull**

Hold the Syringe in the middle of the Syringe Body with the Needle pointing away from you and pull off the Needle Cap.

⚠️ **Do not put the Needle Cap back on.**

⚠️ **Do not touch the Needle.**

⚠️ **Do not inject if the Needle is damaged**

Inject your medicine immediately after removing the Needle Cap.
**Step 8: Pinch**

Pinch a fold of skin at the injection site, as shown in the picture.

**Step 9: Insert**

Insert the Needle completely into the fold of the skin at roughly a 45º angle.
**Step 10: Push**

Relax the pinch.

Push the Plunger Rod down slowly and steadily as far as it will go until the Syringe is empty.

*Note: You will feel some resistance. This is normal.*

**Step 11: Release and Remove**

Lift your thumb to release the plunger rod until the needle is covered by the needle shield and then remove the syringe from the injection site.

Lightly press a cotton ball or gauze on the injection site if you see any blood.
Do not put the Needle Cap back on.

Do not rub your skin after the injection.

Step 12: Dispose

Dispose of the Syringe and the Needle Cap in a puncture-resistant container.

Do not put the Needle Cap back on.

Always keep the container out of the reach of children.

See “How to Dispose of (Throw Away) Used Syringes”.
INSTRUCTIONS FOR USE

DUPIXENT 200 MG SINGLE-DOSE PRE-FILLED SYRINGE WITH NEEDLE SHIELD

Read the Instructions for Use before using the DUPIXENT Pre-filled Syringe with needle shield.

This device is a Single-dose Pre-filled Syringe (called “Syringe” in these instructions) with a needle shield. It contains 200 mg of DUPIXENT for injection under the skin (subcutaneous injection).

Keep these instructions for future use. If you have any further questions, you should ask your healthcare provider or call 1-800-589-6215.

The parts of the DUPIXENT syringe are shown in this picture.
### Important Information

- **Do not** use the Syringe if it has been dropped on a hard surface or damaged.
- **Do not** use the Syringe if the Needle Cap is missing or not securely attached.
- **Do not** touch the Plunger Rod until you are ready to inject.
- **Do not** inject through clothes.
- **Do not** get rid of any air bubbles in the Syringe.
- **Do not** pull back on the Plunger Rod at any time.
- **Do not** re-use the Syringe.

- It is important that you do not try to give yourself or someone else the injection unless you have received training from your healthcare provider.
- Read all of the instructions carefully before using the Syringe.
- Ask your healthcare provider how often you will need to inject the medicine.
- Ask your healthcare provider to show you the right way to use the Syringe before you inject for the first time.
- Rotate the injection site each time you inject.
- To reduce the risk of accidental needle sticks, each pre-filled syringe has a needle shield that is automatically activated to cover the needle after you have given your injection.

### How to Store DUPIXENT:

- Keep the Syringe(s) out of the reach of children.
- Keep unused Syringes in the original carton and store in the refrigerator between 2°C and 8°C.
- Remove the Syringe from the refrigerator at least 30 minutes before your injection so that it reaches room temperature.
- **Do not** keep DUPIXENT at room temperature for more than 14 days.
- **Do not** shake the Syringe at any time.
- **Do not** heat the Syringe.
- **Do not** freeze the Syringe.
- **Do not** put the Syringe into direct sunlight.

### How to Dispose of (Throw Away) Used Syringes

Put your used Needles and Syringes in a puncture-resistant container right away after use.

**⚠️ Do not dispose of (throw away) the Syringes in your household trash.**

If you do not have a puncture-resistant container, you may use a household container that is:
- made of a heavy-duty plastic;
- can be closed with a tightfitting, puncture-resistant lid, without sharps being able to come out;
- upright and stable during use,
• leak-resistant, and
• properly labeled to warn of hazardous waste inside the container

When your puncture-resistant container is almost full, you will need to follow your provincial or local regulations for the correct way to dispose of it.

Step 1: Remove

Remove the Syringe from the carton by holding the middle of the Syringe Body:

⚠️ Do not pull off the Needle Cap until you are ready to inject.
⚠️ Do not use the Syringe if it has been dropped on a hard surface or damaged.
⚠️ Do not keep DUPIXENT at room temperature for more than 14 days.

Step 2: Prepare

Ensure you have the following:
• the DUPIXENT Pre-filled Syringe with needle shield
• 1 alcohol wipe*
• 1 cotton ball or gauze*
• a puncture-resistant container* (See Step 12)

*Items not included in the carton

Look at the label:
• Check the expiration date
• Check that you have the correct product and dose

⚠️ Do not use the Syringe if the expiration date has passed.
Step 3: Inspect

Look at the medicine through the viewing window on the Syringe:

Check if the liquid is clear and colorless to pale yellow.

*Note: You may see an air bubble; this is normal.*

⚠️ **Do not use the Syringe if the liquid is discolored or cloudy, or if it contains visible flakes or particles.**

Step 4: Wait 30 minutes

Lay the Syringe on a flat surface and let it naturally warm to room temperature for at least 30 minutes.

⚠️ **Do not heat the Syringe.**

⚠️ **Do not put the Syringe into direct sunlight.**

⚠️ **Do not keep DUPIXENT at room temperature for more than 14 days.**
Step 5: Select

Select the injection site.
- You can inject into your thigh or abdomen, except for the 5 cm (2 inches) around your navel (belly-button).
- If somebody else gives you the injection, you can also use the upper arm.
- Change the injection site for each injection.

⚠️ Do not inject into skin that is tender, damaged or has bruises or scars.

Step 6: Clean

Wash your hands.

Clean the injection site with an alcohol wipe.

Let your skin dry before injecting.

⚠️ Do not touch the injection site again or blow on it before the injection.
Step 7: Pull

Hold the Syringe in the middle of the Syringe Body with the Needle pointing away from you and pull off the Needle Cap.

⚠️ Do not put the Needle Cap back on.

⚠️ Do not touch the Needle.

⚠️ Do not inject if the Needle is damaged

Inject your medicine immediately after removing the Needle Cap.

Step 8: Pinch

Pinch a fold of skin at the injection site, as shown in the picture.
**Step 9: Insert**

Insert the Needle completely into the fold of the skin at roughly a 45º angle.

**Step 10: Push**

Relax the pinch.

Push the Plunger Rod down slowly and steadily as far as it will go until the Syringe is empty.

*Note: You will feel some resistance. This is normal.*
Step 11: Release and Remove

Lift your thumb to release the plunger rod until the needle is covered by the needle shield and then remove the syringe from the injection site.

Lightly press a cotton ball or gauze on the injection site if you see any blood.

⚠️ Do not put the Needle Cap back on.

⚠️ Do not rub your skin after the injection.
**Step 12: Dispose**

Dispose of the Syringe and the Needle Cap in a puncture-resistant container.

⚠️ **Do not put the Needle Cap back on.**

Always keep the container out of the reach of children.

See “How to Dispose of (Throw Away) Used Syringes”.

![Diagram of disposing of a syringe and needle cap](image)
DUPIXENT 300 mg SINGLE-DOSE PRE-FILLED SYRINGE

Read the Instructions for Use before using the DUPIXENT Pre-filled Syringe.

This device is a Single-dose Pre-filled Syringe (called “Syringe” in these instructions). It contains 300 mg of DUPIXENT for injection under the skin (subcutaneous injection).

Keep these instructions for future use. If you have any further questions, you should ask your healthcare provider or call 1-800-589-6215.

The parts of the DUPIXENT syringe are shown in this picture.

*The device may have either a soft or hard Needle Cap.*
### Important Information

- **Do not** use the Syringe if it has been damaged.
- **Do not** use the Syringe if the Needle Cap is missing or not securely attached.
- **Do not** touch the Plunger Rod until you are ready to inject.
- **Do not** inject through clothes.
- **Do not** get rid of any air bubbles in the Syringe.
- **Do not** pull back on the Plunger Rod at any time.
- **Do not** re-use the Syringe.

- It is important that you do not try to give yourself or someone else the injection unless you have received training from your healthcare provider.
- Read all of the instructions carefully before using the Syringe.
- Ask your healthcare provider how often you will need to inject the medicine.
- Ask your healthcare provider to show you the right way to use the Syringe before you inject for the first time.
- Rotate the injection site each time you inject.

### How to Store DUPIXENT:

- Keep the Syringe(s) out of the reach of children.
- Keep unused Syringes in the original carton and store in the refrigerator between 2°C and 8°C.
- Remove the Syringe from the refrigerator at least 45 minutes before your injection so that it reaches room temperature.
- **Do not** keep DUPIXENT at room temperature for more than 14 days.
- **Do not** shake the Syringe at any time.
- **Do not** heat the Syringe.
- **Do not** freeze the Syringe.
- **Do not** put the Syringe into direct sunlight.

### How to Dispose of (Throw Away) Used Syringes

Put your used Needles and Syringes in a-puncture-resistant container right away after use.

⚠️ **Do not dispose of (throw away) the Syringes in your household trash.**

If you do not have a puncture-resistant container, you may use a household container that is:
- made of a heavy-duty plastic;
- can be closed with a tightfitting, puncture-resistant lid, without sharps being able to come out,
- upright and stable during use,
- leak-resistant, and
- properly labeled to warn of hazardous waste inside the container

When your puncture-resistant container is almost full, you will need to follow your provincial or local regulations for the correct way to dispose of it.
Step 1: Remove

Remove the Syringe from the carton by holding the middle of the Syringe Body:

⚠️ Do not pull off the Needle Cap until you are ready to inject.

⚠️ Do not use the Syringe if it has been damaged.

⚠️ Do not keep DUPIXENT at room temperature for more than 14 days

Step 2: Prepare

Ensure you have the following:

- the DUPIXENT Pre-filled Syringe
- 1 alcohol wipe*
- 1 cotton ball or gauze*
- a puncture-resistant container* (See Step 12)

*Items not included in the carton

Look at the label:

- Check the expiration date
- Check that you have the correct product and dose
Do not use the Syringe if the expiration date has passed.

**Step 3: Inspect**

Look at the medicine in the Syringe:

Check if the liquid is clear and colorless to pale yellow.

*Note: You may see an air bubble; this is normal.*

⚠️ Do not use the Syringe if the liquid is discolored or cloudy, or if it contains visible flakes or particles.

**Step 4: Wait 45 minutes**

Lay the Syringe on a flat surface and let it naturally warm to room temperature for at least 45 minutes.

⚠️ Do not heat the Syringe.
Do not put the Syringe into direct sunlight.

Do not keep DUPIXENT at room temperature for more than 14 days.

Step 5: Select

Select the injection site.
- You can inject into your thigh or stomach, except for the 5 cm (2 inches) around your navel (belly-button).
- If somebody else gives you the injection, you can also use the upper arm.
- Change the injection site for each injection.

Do not inject into skin that is tender, damaged or has bruises or scars.
**Step 6: Clean**

Wash your hands.

Clean the injection site with an alcohol wipe.

Let your skin dry before injecting.

⚠️ **Do not touch the injection site again or blow on it before the injection.**

**Step 7: Pull**

Hold the Syringe in the middle of the Syringe Body with the Needle pointing away from you and pull off the Needle Cap.
⚠️ Do not put the Needle Cap back on.
⚠️ Do not touch the Needle.
⚠️ Do not inject if the Needle is damaged

Inject your medicine immediately after removing the Needle Cap.

Step 8: Pinch

Pinch a fold of skin at the injection site, as shown in the picture.
**Step 9: Insert**

Insert the Needle into the fold of the skin at roughly a 45° angle.

![Insert](image1.png)

**Step 10: Push**

Relax the pinch.

Push the Plunger Rod down slowly and steadily as far as it will go until the Syringe is empty.

*Note: You will feel some resistance. This is normal.*

![Push](image2.png)

**Step 11: Remove**

Pull the Needle out of the skin at the same angle it was inserted.

⚠️ **Do not put the Needle Cap back on.**
Lightly press a cotton ball or gauze on the injection site if you see any blood.

⚠️ **Do not rub your skin after the injection.**

---

**Step 12: Dispose**

Dispose of the Syringe and the Needle Cap in a puncture-resistant container.

⚠️ **Do not put the Needle Cap back on.**

Always keep the container out of the reach of children.

See “How to Dispose of (Throw Away) Used Syringes”.
INSTRUCTIONS FOR USE

DUPIXENT 300 MG SINGLE-DOSE PRE-FILLED PEN

Read the ‘Instructions for Use’ before using the DUPIXENT Pre-filled Pen. Do not inject yourself or someone else until you have been trained by a healthcare professional on how to prepare a dose and inject DUPIXENT. In adolescents 12 years of age and older, it is recommended that DUPIXENT be administered by, or under supervision of, an adult.

This device is a Single-dose (single-use) Pre-filled Pen. It contains 300 mg of DUPIXENT for injection under the skin (subcutaneous injection).

Keep these instructions for future use. If you have any further questions, you should ask your healthcare professional or call 1-800-589-6215.

The parts of the DUPIXENT Pre-filled Pen are shown in this picture.

Important Information:

- Read all of the instructions carefully before using the Pre-filled Pen.
- Ask your healthcare professional how often you need to inject the medicine.
- Choose a different injection site for each injection.
- Do not use the Pre-filled Pen if it has been damaged.
- Do not use the Pre-filled Pen if the Green Cap is missing or not securely attached.
- Do not press or touch the Yellow Needle Cover with your fingers.
- Do not inject through clothes.
- Do not remove the Green Cap until just before you give the injection.
- Do not try to put the Green Cap back on the Pre-filled Pen.
- Throw away (dispose of) the Pre-filled Pen right away after use. See “Step D: Dispose” below.
- Do not re-use a Pre-filled Pen.
How should I store DUPIXENT?

- Keep the Pre-filled Pen(s) and all medicines out of the reach and sight of children.
- Store unused Pre-filled Pens in the refrigerator between 2°C and 8°C (36°F and 46°F).
- Store Pre-filled Pens in the original carton to protect it from light.
- Do not keep Pre-filled Pens at room temperature (less than 25°C (77°F)) for more than 14 days. Throw away (dispose) any Pre-filled Pens that have been left at room temperature for more than 14 days.
- Do not shake the Pre-filled Pen.
- Do not heat the Pre-filled Pen.
- Do not freeze the Pre-filled Pen.
- Do not put the Pre-filled Pen into direct sunlight.

A: Prepare

A1. Gather supplies

Ensure you have the following:

- the DUPIXENT Pre-filled Pen
- 1 alcohol wipe*
- 1 cotton ball or gauze*
- a sharps (puncture resistant) disposal container* (See Step D)

* Items not included in the carton

A2. Look at the Label

- Confirm that you have the correct product and dose.

A3. Check Expiration Date
- Check the expiration date.

⚠ Do not use the Pre-filled Pen if the expiration date has passed.
A4. Check the Medicine

Look at the medicine through the window on the Pre-filled Pen:

Check to ensure the liquid is clear and colorless to pale yellow.

*Note: You may see an air bubble; this is normal.*

⚠️ **Do not use the Pre-filled Pen if the liquid is discolored or cloudy, or if it contains visible flakes or particles.**

⚠️ **Do not use the Pre-filled Pen if the window is yellow.**
**A5: Wait 45 minutes**

Place the Pre-filled Pen on a flat surface and allow it to warm to room temperature (less than 25°C (77°F)) for at least 45 minutes.

⚠️ **Do not heat the Pre-filled Pen.**

⚠️ **Do not put the Pre-filled Pen into direct sunlight.**

⚠️ **Do not keep DUPIXENT at room temperature for more than 14 days. Dispose (throw away) any DUPIXENT Pens that have been left at room temperature for longer than 14 days.**
### B. Choose your injection site

**B1. Recommended injection sites are:**

- **Thigh**
- **Abdomen** except for the 5 cm (2 inches) around your belly button (navel).
- **Upper Arm** If a caregiver gives your dose, they can also use the outer area of the upper arm.

Choose a different injection site for each DUPIXENT injection. If you need a second injection to complete your dose then leave at least 5 cm (2 inches) between the two injection sites.

⚠️ **Do not inject through clothes.**

⚠️ **Do not inject into skin that is tender, damaged, bruised or scarred.**

### B2. Wash Your Hands
### B3. Prepare the injection site
- Clean the injection site with an alcohol wipe.
- Let your skin dry before injecting.

⚠️ **Do not touch the injection site again or blow on it before the injection.**

### C. Give injection

#### C1. Remove Green Cap

Pull the Green Cap straight off.

*Do not* twist the Green Cap off.

*Do not* remove the Green Cap until you are ready to inject.

⚠️ **Do not press or touch the Yellow Needle Cover with your fingers. The Needle is inside.**

⚠️ **Do not put the Green Cap back on the Pre-filled Pen after you have removed it.**
C2. Place

- When placing the Yellow Needle Cover on your skin, hold the Pre-filled Pen so that you can see the Window.

- Place the Yellow Needle Cover on your skin at approximately a 90-degree angle.

⚠️ Do not press or touch the Yellow Needle Cover with your fingers; the Needle is inside.

C3. Press down

Press and hold the Pre-filled Pen firmly against your skin until you cannot see the Yellow Needle Cover.

- There will be a “click” when the injection starts.

- The window will start to turn yellow.

The injection can take up to 20 seconds.
## C4. Hold firmly

Keep holding the Pre-filled Pen firmly against your skin.

- You may hear a second click.
- Check that the entire window has turned to yellow.
- Then slowly count to 5.

If the window does not turn completely yellow, remove the pen and call your healthcare professional.

⚠️ **Do not give yourself a second dose unless instructed by your healthcare professional.**
### C5. Remove

- After you have completed your injection, pull straight up to remove Pre-filled Pen from the skin.

- If you see any blood at the site, lightly dab the site with a clean cotton ball or gauze pad.

⚠️ **Do not rub your skin after the injection.**
D. Dispose

- Dispose (throw away) your used DUPIXENT Pre-filled Pens, (Needle inside), and Green Caps in a puncture resistant (sharps disposal) container right away after use.

**Do not** dispose (throw away) the used Pre-filled Pens (Needle inside) or Green Caps in your household trash.

⚠️ **Do not put the Green Cap back on the Pre-filled Pens.**